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 Four experiments were conducted to characterize the microbiome of the piglet 
and observe effects of diet on growth performance and immunity. In Exp. 1, 96 nursery 
piglets were fed varying carbohydrate sources and in Exp. 2, 64 piglets were fed a soy 
protein concentrate or soybean meal as-is or supplemented with an isoflavone 
concentrate. Body and feeder weights were measured for growth performance estimation. 
Luminal contents and scrapings were isolated for microbial composition analysis. Fecal 
and blood samples were extracted in Exp. 2 for microbiome and immunity analysis. Diets 
did not affect growth performance (P > 0.10); however, Exp. 1 piglets had greater 
average daily feed intake of the experimental diets in phase 1 (P < 0.05). There were no 
differences in microbiome composition among diets (P > 0.10), but a trend over time (P = 
0.11). Differences in microbial composition between sampling locations were shown in 
Exp. 1 and 2 (P < 0.01). In Exp. 2, diet and time altered microbial diversity (P < 0.001). 
IL-8 was not influenced by diet, (P > 0.10) but increased over time (P < 0.001). In Exp. 3, 
IPEC-J2 cells were treated with varying doses of the isoflavone genistein, 
lipopolysaccharides (LPS), or polyinosinic:polycytidylic acid (poly I:C). In Exp. 4, cells 
were treated with the isoflavones genistin, genistein, daidzin, or daidzein, and poly I:C or 
    
diclofenac sodium salt. Media from the basolateral membrane or apical membrane sides 
were used for IL-8 ELISA and TEER was measured to estimate epithelial integrity. In 
Exp. 3, LPS showed greatest electrical resistance (P = 0.014) unlike Exp. 4 that showed 
no differences in TEER for time or treatment (P > 0.10) In Exp. 3 and 4, IL-8 
concentration increased over time (P < 0.01) and was greater in the BLM (P < 0.05). In 
Exp. 4, IL-8 production from the poly I:C treatment was greater than the other treatments 
(P = 0.0186). In conclusion, characterization of the microbiome is influenced by diet, 
time and sampling location. Immune parameters were not different in the in vitro or in 
vivo trial with isoflavones and diet did not affect growth performance. 
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INTRODUCTION 
Nutritional intervention is becoming a staple in the livestock industry with the 
new implementation of the Veterinary Feed Directive prohibiting the use of non-
prescribed antibiotics in feed and leaving producers wondering how they might protect 
their livestock from disease. Gut health improvement has recently become a popular topic 
for preventing the spread of pathogens and is necessary as disease is the greatest 
contributor to economic losses in the livestock industry with the U.S. exporting $6.32 
billion in pork in 2016 alone (Schulz et al., 2016) and a concern for mortality in humans. 
Researchers and producers are striving to discover compounds found in common feed 
sources that could be isolated and supplemented to positively influence the 
gastrointestinal microbiota while minimizing the use of antibiotics. The integration of gut 
bacteria colonization and maturation of the immune system has been widely accepted as 
valuable in managing and preventing disease by using alternative diet ingredients to 
manipulate microbial composition and influence immune parameters as a less invasive 
method than antibiotic use (Filippis et al., 2018). Antibiotics have also been found to 
lower the immune system by deteriorating both beneficial and detrimental microbes, 
creating the need for other medicinal factors that could be implemented while leaving the 
microbiome intact. If the microbiome is able to sustain a healthy environment and 
enhance immune responses through nutritional intervention, the slower the onset of 
disease could be, providing researchers and producers more time to diagnose and treat 
disease before a devastating impact ensues. 
Immunity is represented by the presence of microbes that are able to fend off 
invading pathogens and can be influenced by gut health as well as extrinsic and intrinsic 
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factors of the immune system. This can be measured both in vivo and in vitro by 
quantifying cytokine levels, T cell functionality, monocytes, and others. Researchers are 
interested in conducting experiments where adequate data are measured with the least 
cost and time, creating a demand for cell culture trials, including a cell line cultured from 
the jejunum of an unsuckled neonatal piglet. To determine if an experiment is worth the 
time, money, and effort put into a live animal trial, it’s reassuring to first have a response 
in an in vivo trial.  
The objective of this chapter is to review the development and composition of the 
microbiome, the immune parameters that may be studied, measured, or influenced, and 
discuss an epithelial cell line used in nutritional studies. 
 
THE GUT MICROBIOME 
Background 
The gut microbiome consists of a dynamic microbial population that influences 
the phenotype of a mammal and represents the community of intestinal microorganisms. 
It historically was referred to as microflora, until non-bacterial elements such as archaea, 
fungi, and viruses that also regularly inhabit the gut were accounted for (Quigley et al., 
2013). While it maintains a symbiotic relationship with the host, an imbalance of 
microbes, such as during times of stress, causes susceptibility to disease (Rea et al., 
2016). Antibiotics have been used to combat symptoms; however, there has been concern 
that anti-microbial resistant bacteria has developed and resulted in a demand for 
decreased use of antibiotics by the public (Dibner et al., 2005), increasing the need for 
nutritional intervention. Diet of the host and microbes is critical to the digestion and 
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absorption of nutrients, contributing to the integrity of the intestinal epithelial layer that 
prevents pathogens from invading the host’s gastrointestinal tract (Kyle et al., 2017). 
Diversity follows patterns of community structure, but the microbiome is a unique 
influencer of gut health that can be managed through diet and environment. 
 
Development 
The development of the microbiome depends on environment and influences 
mammalian health and prevention of disease. The diversity of microbes, especially in 
young mammals, is crucial to avert autoimmune and inflammatory diseases that may 
result later in life if the microbiome is not properly constructed. One study has shown that 
growth and change in composition of gut microbes starts before the mammal is born by 
contribution of maternal microbiota to the fetus as the fetus initially maintains a sterile 
gastrointestinal tract (GIT); however, this could have been due to contamination of the 
amniotic fluid (Walker et al., 2017). As maturation occurs, the mammalian gut becomes 
home to over 100 trillion bacterial cells (Holman et al., 2017) and the majority of 
microbial development takes place in the first 2-5 years of life. The microbiome is 
influenced by the amount of exposure to a variety of microbes, pathogens, and antibiotics 
in everyday scenarios such as delivery method, environment, lifestyle, genetics, and diet 
(Rodríguez et al., 2015).  
Most studies have shown that the GIT is first inoculated when the infant is 
exposed to maternal vaginal and fecal bacteria during birth. Mammals that experience 
assisted delivery that are not allowed as much exposure to diverse bacterial species have 
been shown to struggle with optimal colonization for the first few years of life (Jakobsson 
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et al., 2013). The first bacteria to populate the GIT in an anaerobic environment include 
Proteobacteria, Prevotella, and Actinobacteria, but the GIT changes to include higher 
abundances of Bacteriodetes and Firmicutes as age sets in (Rodríguez et al., 2015). 
Germ-free animals show the importance of regular development of gut barrier microbiota 
and their functions, as they suffer from compromised immune systems and inhibited 
progress in the epithelium, vasculature, neuromuscular apparatus, and gut endocrine 
system when not exposed to typical microbial environments (Quigley et al., 2013). In the 
swine GIT, Prevotella is the most abundant genus in the adult, but is also commonly 
found in high quantities in humans and some ruminant animals. Colonization is still 
predisposed to change as a result of diet whether, the infant consumes bacteria naturally 
found in milk or if a formula is consumed. Over 700 species of bacteria are found in milk 
(Cabrera-Rubio et al., 2012) which stimulates colonization of Bifidobacterium that’s 
originally introduced to the microbiome during birth. Infants have altered microbial 
composition compared to adults that gradually becomes similar as nutritional needs 
change, reflecting a necessity for different species. As solid food is introduced into the 
diet, butyrate producers such as Bacteroides and Clostridium become more prominent 
throughout adulthood (Neu et al., 2011). Microbiome studies depict similarity of 
microbial composition in all species, contributing to evidence that these studies are 
interchangeable. 
 
Diversity 
Studies focus on alpha- and beta-diversity of the microbiome that measure the 
presence of bacteria within individuals and the variation between individuals, 
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respectively. Diversity indices allow researchers to depict the differences in a community 
and point out rarity while quantifying diversity. As the microbiome is an ever-changing 
environment, diversity is highly variable over time and across human populations; 
however, there have been attempts to establish a core microbiome (Holman et al., 2017). 
The malleability of the microbial composition is crucial, as a more diverse setting will 
optimize colonization resistance where the native microbes prevent the invasion of 
pathogens and even beneficial microbes. A lower presence of species has been associated 
with dysbiosis in the gut and is associated with autoimmune diseases, cardiometabolic 
disease, and obesity (Sacks et al., 2006). In a rapidly fluctuating setting, diversity of 
microorganisms aids in maintaining regular functionality when environmental challenges 
arise and is most influenced during the early stages of life. Population abundance of 
microbes in the gut has been linked to metabolism, homeostasis, and immune 
development and can be altered by close contact with other individuals or material 
ingested (Maslowski et al., 2011). There is a need for more studies that characterize the 
microbial patterns in the environment to further understand the influences on the structure 
of the microbiome and how it becomes established for some microbes compared to 
others. In diet, it has been shown that omnivores have a higher diversity when compared 
to vegetarians, proposing that microbiota composition varies with diet (Maslowski et al., 
2011). Understanding that difference in locations and cultures result in different eating 
habits and sources, microbial diversity varies across the world, even within the same 
species as the African microbiome diversity is greater than Western cultures due to 
further age and exposure (Conlon et al., 2014). Once established in the GIT, microbes 
become more stable as they find their niche and stake claim on the space and nutrients 
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needed for survival. A niche has been described as the complex description of how an 
organism uses its environment depending upon the metabolic properties of the organism 
and are constantly adapting to fill every ecological niche on the planet by fighting for 
resources that determine survival and genetic persistence (Bauer et al., 2018). Events that 
occur as a part of life, such as surgery or infections, can have detrimental impacts on 
diversity as the use of antibiotics can cause the deterioration of beneficial microbial 
populations while attempting to rid of the harmful organisms. The presence of certain 
macronutrients will influence microbiota as the more nutrients to thrive off of, the more 
competitive a species can become and colonize in the gut more efficiently. A study using 
high-fat diets saw an increase in Rikenellaceae in turn for a decrease in Ruminococcaeae, 
a prominent carbohydrate fermenter (Jakobsson et al., 2013). The availability of nutrients 
creates an advantage for some species by competition in the GIT. 
 
Relationship with the host 
The relationship between the microbes that inhabit the gut and their host is highly 
complex and health and disease of the host depend on microbial diversity. The 
development of the GIT microbiota occurs in parallel to the growth, maturation, and 
sprouting of neurons in the young brain (Rea et al., 2016). The microbiota-gut-brain axis 
is a matrix of tissues that communicate to regulate various immune functions based on 
microbial composition in the gut (Rea et al., 2016). The microbes communicate with the 
host by influencing the enteric, sympathetic, and parasympathetic nervous systems to 
activate neuroimmune components of the central nervous system. This close relationship 
is mutually beneficial and contributes to the host’s energy regulation, gut barrier function, 
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pathogen protection, and overall immune system function (Bengmark et al., 2013). The 
human GIT microbiota alone upregulate nearly 2 million genes (Quigley et al., 2013). 
Communication between commensal bacteria and the host induce regulatory cells, such 
as T cells, that consequently produce anti-inflammatory cytokines for the animal (Conlon 
et al., 2014).  
 
Diet in microbes 
Microorganisms are most influenced by macronutrients in the diet and GIT. 
Depending on the presence of starches, fibers, proteins, and other dietary components 
ingested, variation in individual microbial composition can be as unique as a fingerprint. 
 
Carbohydrates 
Carbohydrates are the key carbon and energy sources for microbes, metabolized 
into short-chained fatty acids (SCFA) during fermentation (Conlon et al., 2014). Among 
these SCFA is butyrate that is synthesized by microbes and serves as the principal source 
of metabolic energy for cells located in the colon, or colonocytes. Carbohydrate digestion 
begins in the mouth with enzymatic degradation by salivary amylase. After carbohydrates 
pass through the esophagus into the stomach and enzymes are inactivated in the acidic 
environment, a majority of the carbohydrates enter the small intestine. The mammalian 
genome does not encode a large enough quantity of the enzymes required for 
carbohydrate degradation, signifying the need for microbial fermentation using 
carbohydrate active enzymes, or CAZymes (Flint et al., 2012). The prominent families of 
Bacteroidetes, Actinobacteria, and Firmicutes possess the greatest quantity of CAZymes 
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that degrade specific polysaccharides, depending upon their location in the GIT, as shown 
in Table 1. Firmicutes and Bacteroidetes pathways are specific to fructan, lactose, and 
starch metabolism and the CAZymes increase degradation of these carbohydrates in the 
extracellular space, cytoplasm, and periplasmic space (Wang et al., 2019). The 
microbiota show flexibility in that they’re able to transition between metabolizing diet 
and host-derived carbohydrates, proving they’re not limited to metabolizing only waste 
after physical and chemical degradation by the host. The structure of the carbohydrates 
influences microbial composition because the bacterial community depends on the 
availability of simple carbohydrates (Zoetendal et al., 2012). If non-digestible 
carbohydrates are excluded from the diet, the microbiota will utilize endogenous energy 
sources, including mucin that lines the intestine, which results in the degradation of the 
membrane that serves as epithelial cell protection and increases risk for pathogen 
invasion. While simple starches are readily utilized in the small intestine, resistant 
starches are the largest sources of energy for microbes provided by diet, depending upon 
the degree of processing of the carbohydrate source before the feed is ingested. The host 
and microbiota both depend upon carbohydrates for energy to use in cellular processes 
and for growth by the degradation of complex carbohydrates in cell walls and starches. 
 
Protein 
Bacteria and the host provide proteases and peptidases to hydrolyze proteins into 
peptides and amino acids in the small intestine. These metabolites can be further utilized 
by the host and the microbes, feeding off of one another. Clostridium, Lactobacillis, 
Streptococcus, and Proteobacteria are amongst the leading fermenters of amino acids in 
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the small intestine (Cho et al., 2007). Clostridia and Peptostreptococci manage the amino 
acids that reach the large intestine; however, if too much protein fermentation occurs 
when these residuals reach the colon, cytotoxic metabolites such as ammonia and 
carcinogens can be detrimental to the microbial population if the nitrogen isn’t utilized by 
the microbes (Conlon et al., 2014). The process of degradation in the small intestine is by 
bacteria containing highly active peptidases is extremely efficient; however, not all 
metabolites are utilized in this location and will either enter the bloodstream or continue 
into the colon to be used by colonocytes. The amino acids utilized undergo de novo 
synthesis to produce other amino acids, such as lysine, particularly in the large intestine 
where microbes harbor a voluminous number of genes used in essential amino acid 
biosynthesis (Sacks et al., 2006). Amino acids may also be used by anaerobic bacteria as 
a precursor for the SCFA acetate and butyrate. Another SCFA, propionate, is exclusive  
to synthesis from threonine, providing alternative energy sources to carbohydrates. This 
is a significant consideration for trials exploring carbohydrate sources, as the protein 
content must be similar. 
 
Lipids 
The digestion of lipids by microbiota is less clear as a majority of studies assumed 
that fat was digested mainly in the small intestine. It has been shown that microbes only 
influence certain aspects of lipid metabolism, including body mass index as well as 
composition of triglycerides and high-density lipoproteins. Most fats are regulated by bile 
acids present in the small intestine, and facultative and anaerobic bacteria produce 
secondary bile acids that subsequently impact glucose metabolism once immersed in the 
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bloodstream (Ghazalpour et al., 2016). These bacteria also participate in complex 
carbohydrate fermentation, influencing the production of SCFA that influence immunity 
and have hormonal effects in the host. The microbiota also produce fatty acid oxidation 
precursors that enhance lipid metabolism, such as trimethylamine N-oxide (Ghazalpour et 
al., 2016). The role of microbiota in lipid digestion is less clear than other 
macromolecules and further experimentation is needed to determine the effect that GIT 
microbes have on fat and vice versa. 
 
Gut health in relationship to disease  
Understanding that providing a complete diet to not only the host, but the 
microorganisms in the gut influences immune functions, it’s apparent that the welfare of 
both the microbiome and the host depends on optimal gut health. Microbes regulate 
stress, the disturbance of the homeostasis of an organism, preventing neuroinflammation 
that has been attributed to psychiatric disorders such as anxiety and depression (Koonin 
et al., 2012). During times of stress, a loss in lactic acid producing bacteria is observed, 
which results in an increase of pH. This results in enhanced disease susceptibility as a 
low pH is crucial in the gut to maintain a bacteriocidal environment that invading 
pathogens cannot normally survive in. If disease is on setting, the host and microbiome 
may also develop a negative relationship where the host cannot recognize the normal 
flora and an inflammatory response ensues that damages the epithelial lining and results 
in bacteria entering the intestinal wall, submucosa, and circulation (Quigley et al., 2013). 
Maintaining positively progressing gut health can prevent pathogen invasion by 
regulating normal bodily functions and maintaining homeostasis by use of the beneficial 
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metabolites supplemented by microorganisms in the GIT.  When antibiotics are 
introduced to the microorganisms, they eliminate not only the problematic bacteria, but 
the beneficial microbes as well, resulting in a clean slate in the GIT for different 
pathogens to enter cause disease (Quigley et al., 2013). A situation that compromises 
pathogens without disturbing the entire microbiome could therefore enhance the immune 
response of the host by maintaining the desired microbial responses to disease. 
 
SOYBEAN-DERIVED ISOFLAVONES 
Background of isoflavones  
Isoflavones are antinutritional factors that have recently gained attention for their 
estrogenic properties and effects on hormone-dependent and age-related diseases, such as 
cancer. Isoflavones are a class of flavonoids, polyphenolic compounds commonly found 
in plants and fungus that are sought after for their antioxidant, antimicrobial, anti-
carcinogenic, and anti-inflammatory properties. Found in legumes and soy foods, their 
structures resemble estrogen, thus binding to estrogen receptors in mammals to apply 
either a weak estrogenic or antagonistic effect. Hormonal regulation by the host can 
decrease estrogenic binding to receptors, depending on potency of other estrogen factors. 
Besides exerting estrogenic and antiestrogenic properties depending upon dosage, 
isoflavones are also protein tyrosine kinase (PTK) inhibitors (Andres et al., 2007).  
Genistein and daidzein are the bioactive forms that are cleaved by -glucosidases in the 
gut microbiota and host cells during digestion from the zymogens genistin and daidzin. 
(Chen et al., 2005). While not all soy products have the same quantity of isoflavones due 
to processing methods, soybean meal, a feed ingredient regularly used in livestock diets, 
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contains a modest amount that could be further supplemented to attempt to regulate 
hormonal processes and enrich the gut microbiota.  
 
Bioavailability and metabolites/digestion 
Isoflavones are the most well utilized of the flavonoid family and genistein has 
been proven to possess the greatest bioavailability (Yu et al., 2016). An unrefined 
soybean will contain between 26-381 mg/100 g of isoflavones that gradually decreases 
with degradation from processing, such as when heated. When ingested, soy isoflavones 
are primarily found in the glycosidic form (daidzin, genistin, and glycitin) before β-
glycosidases in bacteria cleave the glycosidic groups to their aglycosidic form (daidzein, 
genistein, and glycitein) in the jejunum, making them bioactive (Aglin et al., 2013). Once 
activated, the isoflavones are either absorbed intact or further metabolized by the 
intestinal microbiota to metabolites such as O-glucuronides, equol, and sulphate esters in 
the gut barrier before metabolism in the liver (Zubik et al., 2003). S-equol, a non-steroidal 
estrogen metabolized from daidzein, is only produced by 30-50% of the bacterial 
population and is a potent antioxidant that binds to estrogen receptors with greater 
affinity than daidzein (Frankenfeld et al., 2011). This occurs mainly when isoflavones are 
not hydrolyzed or absorbed in the intestine and enter the colon. Genistein is metabolized 
into dihydrogenistein by bacteria and daidzein is metabolized into dihydrodaidzein, as 
shown in Figure 1. Once daidzein becomes 5-hydroxy-equol or generic equol, these 
metabolites will bind to the estrogen receptors, particularly ER-β (Anupongsanugool et 
al., 2005). Isoflavones may be absorbed and exert hormonal activity effects at any point 
of digestion, but are dependent upon intestinal microbiota composition for the extent of 
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metabolism and determining which metabolites are formed. When configuring 
bioavailability and concentration of isoflavones in samples after digestion, it must be 
taken into consideration that the glycosidic forms will be reduced as a consequence of the 
β-glucosidase activity. 
 
Anti-viral and anti-inflammatory properties 
Inflammation is a biological response to harmful stimuli and control is tightly 
regulated to prevent the over-reaction of the innate immune response. Isoflavones are 
well-known for their capabilities to battle disease through their antioxidant, antimicrobial, 
and anti-inflammatory properties both in vivo and in vitro. Isoflavones have been proven 
to down-regulate cytokine-induced signal transduction and reduce leukocyte numbers in 
the blood while decreasing IL-6, nitric oxide (NO), and prostaglandin E 2 (PGE2); 
(Chinta et al., 2012). Inhibition of pro-inflammatory genes, such as COX-2 by genistein, 
propose that the suppression of mediators that induce undesirable responses will delay the 
onset of diseases, such as Parkinson’s Disease, with increased soy consumption. Daidzein 
inhibits oxidative induction of the MAP kinase-NFκB signaling pathway that mediates 
inflammatory responses and is a key factor in pathogenesis of several diseases 
(Lamartiniere et al., 2002).  
Antiviral properties are most elicited by genistein to inhibit the infectivity of a 
range of DNA and RNA viruses. Isoflavones also influence cell membrane structures and  
regulate interactions with tight junction multiprotein complexes that are activated during 
stress to prevent invading pathogens from entering the enterocytes of the small intestine. 
Additive immune properties from the consumption of soy-based infant formulas decrease 
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rotavirus infection that causes performance loss through upset stomach that results in 
diarrhea and vomiting in young mammals (Andres et al., 2007). Dietary supplementation 
induces immune responses by activating factors such as cytokine production from T cells 
that mobilize neutrophils to sites of infection, inhibiting natural killer cell cytotoxicity 
that are crucial to the innate immune system, and even the inhibition of IgE receptor 
signaling that results in the prevention of allergies (Sakai et al., 2008). When activated, 
genistein has been identified as a potent inhibitor of protein tyrosine kinase (PTK) 
activity associated with epidermal growth factor receptor (Brosnahan et al., 2012). PTKs  
regulate cellular activities, such as cell division and in some cases, can be mutated and 
result in uncontrollable cell division, resulting in cancer. Genistein has been shown to 
inhibit DNA topoisomerase II, an enzyme that regulates DNA overwriting and 
underwriting, and the prevention of these actions results in permanent DNA strand breaks 
that overwhelm the cellular processes for repair and initiate apoptosis instead (Andres et 
al., 2007). More experimentation focusing on the mechanisms of the antiviral properties 
are of interest as it has not be confirmed that PTK inhibition, DNA topoisomerase II 
inhibition, and timing of exposure to isoflavones have an effect on infectivity of 
pathogens. It is suspected that the antiviral mechanism is related to a binding or 
postbinding event in viral cell entry and replication.  
 
Impact on microbiome  
There is a dependence on the microbiome to perform metabolism, thus emphasis 
is made on the intestinal bacterial profiles of the consumers to determine efficiency; 
however, some phenolic compounds, such as isoflavones, have been found to be 
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antimicrobial. The baseline microbiome composition dictates how polyphenols are 
metabolized because both beneficial bacteria and pathogens are predisposed to 
isoflavones and their inhibitory effects. Some studies have contributed the contradictory 
effects of isoflavones on the bioavailability to produce equol, but recent evidence relates 
these effects to the presence of sulphate reducing bacteria (Nakatsu et al., 2014). Few 
studies have focused on the characterization of the microbiome with soy intake, but most 
identified an increase in Eubacterium and Bifidobacterium (Paul et al., 2017). 
Bifidobacteria is known to thrive off of isoflavone metabolites and it has been observed 
that Clostridium is higher in abundance in individuals capable of producing equol (Bolca 
et al., 2007). It would be of interest to examine human microbial populations in Asian 
countries where soy is a common dietary component compared to the average Western 
diet that commonly excludes soy and isolate the bacteria more abundant in the Asian 
microbiome and determine which are capable of producing equol. Further 
experimentation is needed to characterize the microbiota that suffer or flourish as a result 
soy consumption to better understand which cultures or environments are ideal for 
isoflavone supplementation.   
 
In relation to cancer and infertility 
Firm effects of isoflavones on cancer are yet to be determined; however, studies 
show that higher malignancy incidences are related to S-equol binding to β-estrogenic 
receptors (Anupongsanugool et al., 2005). 6’-Hydroxy-O-demethylangolensin (6’-OH-
DMA) is a metabolite of genistein that has stronger estrogenic properties than the parent 
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compound and can be absorbed by the intestinal mucosa or the liver (Matthies et al., 
2008). 6’-OH-DMA is conjugated to O-DMA glucuronide and O-sulfate before released 
into circulation or bile (Frankenfeld et al., 2011). In a more targeted approach, it was 
discovered that a decrease in 17β-estradiol glucuronidation resulted in an increase in risk 
of breast cancer development with excess consumption of isoflavone supplements in 
patients diagnosed with ERα breast cancer (Dong et al., 2010). Cancer is a pleiotropic 
disease and genistein is a pleiotropic compound, giving rise to opportunities for 
undesirable events to transpire when combined. There are cases that show that the 
introduction of isoflavones into cancer patients causes cell proliferation, accelerating 
cancer invasion (Kurzer et al., 2000). These results depend on the health status, age, sex, 
and the presence or absence of specific gut microflora as only some populations are able 
to metabolize the phytoestrogens and are not as abundant in Western cultures. Most 
contribute the adverse effects and increased cancer cell proliferation on the type of 
estrogen receptor more prominent in the individual and if the patient is pre- or post-
menopause, as women harboring more ER-α receptors that are post-menopausal are more 
prone to the undesirable effects (Russo et al., 2016). Impaired fertility is another downfall 
that has resulted from the use of isoflavones. In the neonatal mouse model, mice could 
not deliver live pups after subcutaneous genistein exposure, showing that estrogen’s 
mechanism in the female reproductive tract is mediated through ER-α (Barnes et al., 
2011). In premenopausal women, isoflavones decrease midcycle luteinizing hormone and 
follicle stimulating hormone concentrations. These side effects impair growth of ovarian 
follicles before the release of eggs (Kurzer et al., 2000). While women experienced a 
decrease in breast cancer risk as a result of an increase in menstrual cycle length and 
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decreased urinary estrogen excretion, these side effects are both indications of lower 
fertility rates. In male subjects, mature sperm decrease when exposed to a high dietary 
dose of genistein and reduce testis and epididymis indexes, lactate dehydrogenase, and 
overall testosterone levels, negatively effecting reproductive function (Yuan et al., 2012). 
Adverse effects on reproduction and in cancer patients raise concerns for the use of 
dietary isoflavones and leave researchers wondering if the beneficial effects outweigh the 
detrimental outcomes. The question remains how to obtain the advantageous results with 
lowered risk for the unfavorable outcomes. These situations represent the need for 
individual characterizations and studies because there are many factors that contribute to 
the hormone therapy that ensues with isoflavones. 
 
IPEC-J2 CELL LINE 
Background 
IPEC-J2 cells are a columnar intestinal porcine enterocyte cell line that are 
cultured from the epithelium of the jejunum in a unsuckled neonatal piglet. They were 
originally cultured by Helen Berschneider at the University of North Carolina in 1989 to 
examine transepithelial ion transport and proliferation (Berschneider et al., 1989). They 
are unique in that are not transformed, meaning they have a slower growth rate and lower 
plating efficiency than transformed cell lines and are derived from small intestinal tissue 
(Chopra et al., 2010). Small intestine cell lines have far less evidence when compared to 
the colon, even though these cell lines are highly resistant to injury and when harmed, 
apoptosis swiftly occurs and sloughs off the dead cells into the lumen. There is interest of 
the epithelial monolayer in the gut as it serves as a physical barrier to prevent harmful 
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microorganisms from invading the mucosa and averts infection. Thus, the functional 
integrity of the epithelial cell lines must be able to combat the multiple mechanisms of 
invasion by pathogens. IPEC-J2 are quickly becoming a prominent in cell culture studies 
due to their integrity, use in numerous assays, and ease of handling. 
 
Characterization 
A polarized monolayer is formed when IPEC-J2 cells are cultured and the use of 
fetal bovine serum (FBS) in the culturing medium as opposed to porcine serum results in 
high transepithelial electrical resistance (TEER) to form (Vergauwen et al., 2015). The 
high TEER is useful when investigating tight junctions and low active transport rates 
when challenged with compounds that are harmful to monolayer permeability. Tight 
junction proteins define barrier and permeability functions of the paracellular pathway 
and claudin-3 and -4 and occludin have been found in the apicolateral membrane (AM), 
resembling normal jejunum properties (Schierack et al., 2003). IPEC-J2 contain 
microvilli on the apical membrane side, imitating extension into the lumen and are 
characterized as a continuous cell line with studies using passages up to 98 (Vergauwen 
et al., 2015), proving great longevity. The characterization of the IPEC-J2 cell line for 
pathogenesis studies only took place in 2003 by Schierack; however, this cell line has 
shown the capability to possess very similar properties to human physiology and shows 
specificity to porcine-derived infections, proposing that these cells are viable for viral 
studies including both human and porcine pathogens (Boyen et al., 2009).  
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Immunity studies potential  
IPEC-J2 cells are similar to human cell lines in that they secrete cytokines, 
defensins, and toll-like receptors that all participate in communication between the 
enterocytes and the innate immune system from pathogen recognition receptors. 
Cytokines, such as TNF-α, are secreted by IPEC-J2 proteins and mRNA expression of 
Toll-like receptor(TLRs)-2 through -10 and IL-1α, -1β, -6, -7, -8, -12A, -12B, and -18 
have all been confirmed in these cells (Brosnahan et al., 2005). Presence of protein 
expressions of claudin-1, -5, -7, -8 -12, and tricellulin have also been established by 
immunoblotting (Zakrzewski et al., 2013), telling that a wide range of experiments may 
transpire given the number of variables that can be investigated. These properties have 
already been proven to be valuable in characterization of epithelial cell interactions with 
enteric bacteria and viruses and make IPEC-J2 cells an ideal cell line for investigating 
pathogens (Brosnahan et al., 2012). Similar responses in reference to immune parameters, 
such as IL-8, have been observed in IPEC-J2 cells comparable to a human cell line, 
colonic T84 cells, in response to infection (Vergauwen and Tambuyzer et al., 2015). 
Advantages of using IPEC-J2 cells as a model for normal intestinal epithelial cells 
include their consistency of differentiation characteristics that strongly mimic primary 
intestinal epithelial cells and are directly analogous to the experimental animal that is 
used as an in vivo model for humans. While originally purposed to determine ion 
permeability, IPEC-J2 cells have developed into the most similar cell line of non-human 
origin that can be referenced into human physiology. 
 
 
    21 
SUMMARY 
The gut microbiome is becoming strongly of interest for determining and 
influencing health and immunity. Manipulation of the microbial communities in the GIT 
will affect the digestion and absorption of nutrients from diet that maintain intestinal 
epithelial integrity and contribute to health. The symbiotic relationship between host and 
gut bacteria enable access to nutrients that are not typically available from cellulose and 
other fibrous compounds. The better the microbiome is understood, the more readily 
available nutrients can be delivered to maximize efficiency while determining the 
metabolites formed, such as those produced by isoflavones. While isoflavones have had 
adverse effects on specific bacteria with antimicrobial properties, the anti-inflammatory, 
antiviral, and antioxidant potential are highly sought after, and the detrimental effects 
could be masked when isoflavones are used appropriately. They exert estrogenic activity 
on the host while their metabolites prove to administer an even harsher effect against 
pathogens and disease. To take advantage of these properties, an accurate estimation of 
composition of the gastrointestinal microbiota must be determined for an individual and 
which estrogen receptor present in a higher quantity identified for accurate dosage 
administration of the isoflavones. While this appears to be an individualized process, 
experimentation to gauge the typical abundance of isoflavone metabolizing bacteria in an 
individual will allow for estimation of what could be an industry standard. These 
experiments could take place in an in vivo model but are recommended in vitro first 
because many immune parameters and gene expressions can be measured in a cell culture 
experiment before use in live animals. The integrity of the IPEC-J2 cell line and the 
numerous measurements that can be taken from this intestinal epithelial model are 
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applicable to observe several immune responses that are highly reproducible. IPEC-J2 
cells are robust and could be used for disease challenges to examine how the epithelial 
lining reacts during times of stress and establish a baseline response of small intestine 
epithelial cells to a pathogen. Gut health is a trending topic in the scientific community; 
however, there is still much to characterize before manipulation of the microbiota to 
optimize health and growth performance can occur. Soy isoflavones and their conflicting 
results are a potential solution to the onset of disease; however, further explanation of the 
mechanisms involved in immunity are needed. 
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TABLE AND FIGURE 
Table 1. Predicted CAZymes encoded by the genomes of selected fibrolytic gut bacteria 
(Flint et al., 2012). 
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Figure 1. Metabolic pathway of bioactive isoflavones daidzein and genistein (Kwak et al., 
2009). 
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Chapter 2: Effects of carbohydrate source on performance and gastrointestinal 
microbiota in nursery pigs. 
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ABSTRACT 
  An experiment was conducted to determine the effects of carbohydrate source on 
growth performance and gastrointestinal microbiota in nursery pigs. Ninety-six pigs 
weaned at 21 d were randomly allotted to 16 pens (6 pigs/pen; 4 pens/treatment) with sex 
represented evenly in each pen. Pigs had ad libitum access to feed and water for the 2-
phase nursery period (28 d). Dietary treatments included: 1) NutrisureTM (a food-grade 
cooked cereal grain product), 2) oatmeal (food-grade oatmeal grain), 3) steam-rolled oats 
(SRO), or 4) dried-distiller’s grains as a negative control (DDGS). Ileal and colonic 
digesta and mucosa samples were collected on d 0, 14, and 28 (n = 6, 32, and 32, 
respectively) for analysis of microbial species using IlluminaTM next generation 
sequencing. The DNA sequences were filtered through the DADA2 pipeline, Mothur, and 
QIIME. Pig body weights and feeder weights were also measured on d 0, 7, 14, 21, and 
28. Pigs fed DDGS had lower average daily feed intake (ADFI) compared to other 
treatments during phase 1 (P < 0.05), but there were no differences in average daily gain 
(ADG) or gain:feed (G:F) among treatment. There were no differences among treatments 
for ADFI, ADG, or G:F for phase 2 or the overall experimental period. Microbial 
composition differed significantly among location in the gastrointestinal tract (P < 0.01) 
and among the digesta and mucosa samples extracted from the ileum and colon. 
Lachnospiracae pseudobutyrivibrio and butyrivibrio were identified as the species 
primarily responsible for variation in sample location (P < 0.01). There were no 
significant changes in the microbiota among any treatment (P > 0.10). Over time, there 
was a trend (P = 0.111) for microbial diversty to vary; however, there was no interaction 
among diets or as a result of sampling time point. In conclusion, carbohydrate sources did 
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not affect gastrointestinal microbiota composition, ADFI, ADG, or G:F overall in this 
experiment. However, feed intake during phase 1 differed between DDGS and oat-based 
carbohydrate sources and microbial species were different between digesta and mucosa in 
the ileum and colon. 
Key words: carbohydrate sources, gastrointestinal microbiota, growth performance, 
nursery pig 
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INTRODUCTION 
 
Carbohydrates are the primary source of energy for the gastrointestinal microbiota 
and are used in the production of short chain fatty acids (SCFA) in the bowel as 
fermentation products from food components that are not absorbed or digested in the 
small intestine. Diet has been shown to affect gut microbiota composition and impact 
human and swine health while preventing disease progression (Singh et al., 2017). 
Bacteria in the upper intestinal tract are able to metabolize simple carbohydrates while 
the latter portion includes bacteria that ferment the complex carbohydrates to break down 
the more complicated -1,4 glycosidic bonds found in cellulose, a compound found in 
cell walls in plants (Zoetendal et al., 2012). In order to enhance immune system response, 
energy for biological processes is needed, suggesting there is reliance on the 
carbohydrate structure and source ingested by the host and utilization capabilities of the 
gut microbiota (Round et al., 2009). SCFA strengthen the mucosal barrier and affect 
immunity by inducing responses in toll-like receptor (TLR) expression, antigen 
presenting cells, differentiated T cells, among others (Flint et al., 2012). The microbiome 
has the ability to affect diseases such as inflammatory bowel disease where there is less 
bacterial diversity with an exclusion of prominent carbohydrate digesting bacteria such as 
Bacteroides and Firmicutes (Singh et al., 2017). Evidence shows that Bacteroides and 
Firmicutes interact with one another and contribute to obesity when the abundance ratios 
are out of balance. When this occurs, these bacteria are able to harvest excess energy 
from the host’s diet. In the small intestine, aerobic and facultative anaerobes handle 
simple carbohydrates with ease in a rapid and efficient manner, while strict anaerobes 
colonize in the colon and digest fiber products that must experience fermentation before 
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their nutrients can be utilized (Flint et al., 2012). Understanding which bacteria are 
present in various locations in the GIT makes it possible to individualize medicine and 
prevent and/or treat diseases and metabolic disorders through nutritional intervention 
(Filippis et al., 2018). There is interest in how diets with varying carbohydrate sources 
alter alpha- and beta-diversity of the microbiome when there are varying concentrations 
of readily metabolizable carbohydrates compared to nondigestible carbohydrates included 
in the diet. Pigs can used as a model to determine microbial differences due to their basic 
anatomical and physiological similarities to humans in digestion and absorption (Bassols 
et al., 2014). 
Objective: To determine the effects of simple or complex carbohydrate sources on the 
gut microbiome and growth parameters of nursery piglets while characterizing the 
development and location of the microbiota. 
 
MATERIALS AND METHODS 
Animals 
 A total of 96 terminal cross-bred barrows and gilts were randomly assigned to 16 
pens with 6 pigs/pen and BW of 5.5 ± 0.5 kg with equal representation of sex in each 
pen. The pigs were 21 d of age and the room holding the pigs was temperature controlled. 
The experiment took place over 28 days, pigs had ad libitum access to feed and water for 
the entire duration of the experiment, and sample collection of colonic and ileal digesta 
and mucosa took place immediately after pigs were placed in their respective pens from 
an extra 6 pigs on d 0 without being exposed to any of the nursery diets. 
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Diets and Collection Method 
 Body weight and feeder weights were measured on d 0, 7, 14, 21, and 28 to 
determine average daily feed intake (ADFI), average daily gain (ADG), and gain to feed 
(G:F). Ileal and colonic digesta and mucosa samples were taken on d 0, 14, and 28 from n 
= 6 on d 0 and n = 32 on d 14 and 28. The 4 diets were randomly assigned to 4 pens each 
and included NutrisureTM (a food-grade cooked cereal grain product), oatmeal (food-
grade oatmeal grain), steam-rolled oats (SRO), or dried-distillers grains as a negative 
control (DDGS). Diets comprised of similar inclusions of all ingredients within phase 
with 10% of each carbohydrate source, except for DDGS which was includedxx at 15%, 
as shown in Table 1.1 and 1.2. Less Dairy-lac 80 was needed in the Nutri-Sure and 
Oatmeal diets because these ingredients already contained lactose and adjustments were 
made to include 8% lactose content in every diet. Indispensable amino acids were 
supplemented to meet NRC (2012) requirements for lysine, methionine, and threonine. 
Calcium was supplemented by inclusion of coarse ground limestone and phosphorus was 
supplemented evenly in the diets with the addition of dicalcium phosphate. In phase 2, 
fish meal was not included due to satisfaction of the crude protein content using only 
soybean meal and amino acid supplementation. All NRC (2012) requirements were met 
by nutrient inclusions in every diet and diet composition and calculated nutrient 
composition are illustrated in Tables 1.1-1.4.  
  
DNA Isolation and Sequencing 
A Mag Bind Soil DNA Kit (Omega Bio-tek, Norcross, GA), was used to extract 
DNA from luminal contents and tissue scrapings in both the ileum and the colon and 
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isolated in a KingFischer Isolation system (ThermoFisher Scientific, Waltham, MA). The 
DNA was amplified using polymerase chain reaction and profiled for quality and quantity 
with 1.5% DNA Gel Agarose Electrophoresis. Samples were then normalized using a 
Charm Biotech 96 well Normalization Kit and pooled together, all using an EpMotion 
Robot. Once pooled, the samples were purified using a NucleoSpin Gel and PCR Clean-
Up kit (Takara Bio, Mountain View, CA) and quantified with a Denovix kit and reader 
(DeNovix, Wilmington, DE). Libraries were shown to be eligible for a 2 nM sequencing 
run using a V2 kit with an Illumina Next Generation Sequencer.  
 
Statistical Analysis 
DNA analysis began with the filtering of sequence reads as well as trimming to 
remove chimeras that could alter results. An ASV table was generated in R using Dada2 
and a phylogenetic tree in Mothur. The tree was merged with the ASV table in R, a 
mapping file designed for variables of interest was added, and taxa was assigned from a 
Silva taxonomy package. Bray Curtis distances were generated to determine relative 
abundance measure in the MicrobiomeSeq and DESeq2 packages. Amplicon sequence 
variants (ASVs) were used as opposed to OTUs for more accurate analysis. The Adonis 
and Permanova functions included in the Vegan package were used to generate P-values 
to identify locational effects and which taxa were significantly different. RStudio was 
also used to generate principal component of analysis plots from Bray Curtis values as 
well as alpha diversity.  
Growth performance analysis was determined with a 1-way analysis of variance 
(ANOVA) conducted using the MIXED procedure of SAS 9.4 (SAS Inst. Inc., Cary, NC) 
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to differentiate treatment effects at a significance level of P ≤ 0.05 and trends at a 
significance level of 0.05 < P < 0.15.  
 
RESULTS 
Growth Performance 
 There were no effects of diet (P > 0.10) on ADFI, ADG, BW, or G:F overall. 
However, there was an increase (P = 0.03) in ADFI in wk 1 and 2 for consumption of 
SRO, NS, and OM diets compared to DDGS. As a result, diet produced an increase in 
ADFI in phase 1 (P = 0.02); however, by the time phase 2 began and for the overall 
experiment, there were no differences in growth performance among the diets. This is 
shown in Figures 1.4-1.7 where no differences are detectable.  
 
Microbiome Analysis 
 There were no differences in overall microbial abundances or diversity among 
diets (P = 0.189), but a trend for time to affect microbial composition (P = 0.111). The 
location that samples were isolated from had varying microbial abundances (P = 0.003), 
leading to further analysis to determine which of the 4 locations were different. While it 
was determined that mucosa and digesta differ from each other (P = 0.001), they do not 
differ when extracted from the ileum versus the colon (P > 0.10). Lachnospiraceae 
Pseudobutyrivibrio and Lachnospiraceae Butyrivibrio were the top 2 families that caused 
differences and were most prominent in the mucosa compared to the digesta (P < 0.01). 
Prevotellaceae Prevotella_1 was found in the colonic mucosa (CM) more than any other 
location (P < 0.01), Ruminococcaceae Faecalibacterium was of great abundance in the 
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ileal digesta (ID) (P < 0.01), and Lachnospiraceae Lachnoclostridium was the most 
present genus in the colonic digesta (CD) (P < 0.01) When comparing colonic digesta 
and mucosa, there was a greater abundance of Helicobacteraceae Helicobacter, 
Campylobacteraceae Campylobacter, Prevotellaceae Prevotellaceae, and Rikenellaceae 
Rikenellaceae_RC9_gut_group in the mucosa (P < 0.01) and Erysipelotrichaceae 
Erysipelotrichaceae and Lactobacillaceae Lactobacillus in the digesta (P < 0.01). The 
comparison between ileal mucosa (IM) and CD showed a greater abundance of 
Ruminococcaceae Subdoligranulum, Prevotellaceae Prevotella, Muribaculaceae, 
Prevotellaceae Prevotellaceae_NK3B31_group, Veillonellaceae Megasphaera, 
Lachnospiraceae Coprococcus_3, Lachnospiraceae Dorea, Ruminococcaceae 
Ruminococcaceae, Veillonellaceae Dialister, and Streptococcaceae Streptococcus in the 
colon (P < 0.01). The contrasts between ID and CM showed a greater abundance of 
Campylobacteraceae Campylobacter, Muribaculaceae, Prevotellaceae 
Prevotellaceae_NK3B31_group, Prevotellaceae Prevotella_2, Rikenellaceae 
Rikenellaceae_RC9_gut_group and Enterobacteriaceae Escherichia/Shigella in the CM 
(P < 0.01). The ileal components were compared and showed a greater abundance of 
Veillonellaceae Dialister, Streptococcaceae Streptococcus, Lactobacillaceae 
Lactobacillus, Bifidobacteriaceae Bifidobacterium, Coriobacteriaceae Olsenella, and 
Clostridiaceae_1 Clostridium_sensu_stricto_1 in the ID (P < 0.01) while a great amount 
of unidentified bacteria were prominent in the IM (P < 0.01).  
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DISCUSSION 
Growth performance was not affected by diet overall; however, growth 
performance was affected in weeks 1 and 2 and phase 1. The greater consumption of 
SRO, NS, and OM diets compared to the DDGS could be due to the sweeter smell of 
these diets that are higher in starch and more palatable (Seabolt et al., 2010). If the piglets 
are more likely to eat this diet in the first phase after weaning when stress is high, it’s 
worth noting that if there’s a supplement that requires enhanced feed intake, these diets 
would be better to feed than the DDGS. While there was a difference in feed intake, there 
were still no differences in ADG, G:F, or BW, meaning that even though the feed was 
more well liked, it was not more efficient and cost should be taken into consideration 
when feeding these diets if more product is used with less utilization in the body.  
The gut microbiota composition and diversity were measured in 4 locations in the 
GIT including; luminal contents in the ileum and colon (ID, CD) and scrapings in the 
ileum and colon (IM, CM). Figure 1.3 shows the consistency in bacterial diversity among 
diets, but how composition changes in different sampling locations. There is also a 
presence of the Planctomycetes and Cyanobacteria phyla in this figure, bacteria that are 
found in chloroplasts and participate in photosynthesis. They are included in this study 
because when isolating DNA from the luminal contents, plant DNA residues were 
sequenced because they were extracted from the soybean meal and corn that the pigs 
ingested and were moving through the lumen at the time of sampling. The principal 
component analysis plot in Figure 1.2 shows the clustering of sample location, where 
clustering of one color represents that variable as being similar to itself and not to other 
locations. The abundance of Lachnospiraceae Pseudobutyrivibrio and Lachnospiraceae 
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Butyrivibrio were the most different among sampling location and these taxonomies are 
common to the gut and degrade complex polysaccharides to SCFA (Sagheddu et al., 
2016). These families were harbored in the lining of the gut and protect against infections 
in the humans. It has been shown that low-level subtherapeutic antibiotics optimize 
Lachnospiraceae colonization in the infant mouse and contribute to the development in 
diabetes (Kameyama et al., 2014), most likely due to their energy precursor producing 
abilities. 
 In the CM, Prevotellaceae Prevotella_1 genus was most abundant and secretes 
ghrelin, a gut hormone that maintains dopamine function and upholds GIT motility 
(Gerhardt et al., 2018). Campylobacteraceae Campylobacter colonized in the CM, as 
well and is found in house flies and it has been previously shown that a majority of C. 
Campylobacter contain virulence genes and antibiotic resistance (Scanlon et al., 2013). 
This species is closely related to Muribaculaceae that was also found in the CM as a 
result of the ingestion of flies by the pigs. As far as public health concern goes, this 
discovery should not be of concern if pork is properly cooked and this genus could be a 
target for research to better understand the mechanisms of antibiotic resistance. 
Helicobacteraceae Helicobacter is a known agent of gastrointestinal disease; however, 
some species are not pathogenic (Oxley et al., 2004). Rikenellaceae 
Rikenellaceae_RC9_gut_group had high presence in the CM and participates in lipid 
metabolism, commonly leading to obesity and diabetes (Cani et al., 2013). The bacteria 
present in the CM, the most diverse location in the GIT, showed many beneficial bacteria 
that participated in membrane integrity, while there were species that are pathogenic. 
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This could suggest that there are parts of the GIT that are more prone to infection than 
others and the source of stress is identifiable based on the type of infection.  
In the CD, the abundant Ruminococcaceae Subdoligranulum and 
Ruminococcaceae Ruminococcaceae have been proven to affect gut barrier function and 
participate in colonization resistance against Clostridium difficile, a bacterium associated 
with antibiotic-associated diarrhea (Pérez-Cobas et al., 2014). Veillonellaceae 
Megasphaera are a commensal bacterium with a genome involved in metabolism of 
proteins and amino acids as well as carbohydrates that produce end products beneficial to 
the host, such as SCFA, vitamins, and co-factors for other necessary cell functions 
(Shetty et al., 2013). Lachnospiraceae Coprococcus_3 is a known butyrate producer, one 
of the major sources of energy to the colonic mucosa cells that also participates in 
regulating gene expression, inflammation, differentiation, and apoptosis (Noriega et al., 
2016). The two Prevotellaceae groups, Prevotellaceae Prevotella and Prevotellaceae 
Prevotellaceae_NK3B31_group were among the top 10 families most abundant in the 
CD, which could be the result of sloughing of the intestinal lining, as these genus’s are 
commonly found in the mucosa. The Lachnospiraceae Dorea is a major gas producer in 
the GIT with glucose fermentation end products including hydrogen and carbon dioxide 
(Taras et al., 2002). Veillonellaceae Dialister has been shown to increase the amount of 
circulating IL-6 in the blood serum, a cytokine that communicates with the host to 
stimulate the immune system (Martinez et al., 2012). Lastly, Streptococcaceae 
Streptococcus was abundant in the CM and is known to cause infections, such as 
pharyngitis and impetigo (Walker et al., 2014). The presence of both the beneficial and 
degenerative bacteria agrees with the findings in the CM that pathogenic bacteria may 
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reside in a specific location in the GIT and medicine may be targeted towards those areas 
to prevent an imbalance in earlier sections of the intestine from the effects of antibiotics. 
The digesta samples were not as diverse as the mucosa samples; however, there 
were certain genus’ that appeared more often in the digesta than the mucosa. 
Veillonellaceae Dialister and Streptococcaceae Streptococcus were shown to be in a high 
abundance in the luminal contents more than in the lining. Lactobacillaceae 
Lactobacillus were also copious and is commonly found in probiotics as this genus is 
involved in carbohydrate metabolism to produce lactic acid (Walter et al., 2008). 
Bifidobacteriaceae Bifidobacterium are among the first bacteria that colonize in the GIT 
and are also probiotic organisms that perform health-promoting actions and also 
participate in carbohydrate metabolism (Egan et al., 2018). The Coriobacteriaceae 
Olsenella genus is present in both healthy and acidotic animals and is involved in 
carbohydrate metabolism, producing lactic acid in ruminants and non-ruminants from 
various carbohydrate sources (Kraatz et al., 2010). The Firmicutes family in the ileal 
bacteria community was composed of a high presence of Clostridiaceae_1 
Clostridium_sensu_stricto_1 for protein and amino acid metabolism and utilization (Fan 
et al., 2017); however, it has been shown that a decrease in dietary protein results in an 
increase in this strain of bacteria and improvement of ileal barrier integrity. The digesta is 
continuously moving through the GIT and is subjected to many more microbes than the 
stationary mucosa; however, it maintains less diversity.  
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CONCLUSION 
 Growth performance and the overall gut microbiome were not affected by time or 
diet; however, there were differences in microbial composition when comparing the 
luminal contents and lining. These observations suggest that sample extraction from the 
colon may be representative for bacteria present in the ileum if the microbes isolated are 
from the mucosa or the digesta, but not intermixed. Energy producing bacteria were also 
found in both the ileum and the colon, showing that microbes in the latter portion of the 
intestine do not rely on the energy produced in the former. Complex carbohydrates that 
are broken down during fermentation are useful to supplement these bacteria to keep 
communities diverse and efficient. The Lachnospiraceae family of the Clostridiales order 
is the main cause for variation between digesta and mucosa while originally assumed to 
have been most prominent in the mucosa. This observation agrees with previous studies 
that have shown a greater abundance in the mucosal lining that affects gut integrity and 
energy production. There are many species that differ from sampling location, both 
beneficial and pathogenic, suggesting that phenotype may be influenced by 
supplementation that targets specific sections of the GIT. It is of interest to determine if 
treatment of one part of the intestine without disrupting the microbiome in other parts can 
improve immune status of a sick individual through preservation of the unaffected 
microorganisms that produce health-enhancing co-products. Further characterization of 
the microbiome and the production of metabolites may help provide opportunity for 
specific outcomes through nutritional intervention. 
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TABLES 
Table 1.1. Ingredient composition (% as-fed bases) of diets for Phase 1. 
 
Ingredients, % DDGS SRO NS OM 
Corn 32.6 36.5 39.1 40.3 
Soybean meal, Dehulled, Solvent Extracted 32.0 33.0 33.0 33.0 
Fish Meal 7.00 7.00 7.00 7.00 
Corn DDGS, > 6% and < 9% oil 15.0 0.00 0.00 0.00 
Steam-Rolled Oats 0.00 10.0 0.00 0.00 
Nutrisure 0.00 0.00 10.0 0.00 
Oatmeal 0.00 0.00 0.00 10.0 
Dairylac-80 8.00 8.00 5.40 4.20 
Corn Oil 3.00 3.00 3.00 3.00 
Dicalcium Phosphate 18.5% P 0.40 0.65 0.65 0.70 
Coarse Ground Limestone 0.85 0.70 0.65 0.62 
L-Lys-HCl 0.32 0.32 0.34 0.34 
DL-Met 0.04 0.04 0.06 0.06 
L-Thr 0.06 0.10 0.12 0.12 
Sodium Chloride 0.30 0.30 0.30 0.30 
Vitamin Premix1 0.25 0.25 0.25 0.25 
Trace Mineral Premix2 0.15 0.15 0.15 0.15 
 
1Vitamin premix supplied per kg of diet: vitamin A (as retinyl acetate), 5500 IU; vitamin 
D (as cholecalciferol), 550 IU; vitamin E (as tocopherol acetate), 30 IU; vitamin K (as 
menadione dimethylpyrimidinol bisulfate), 4.4 mg; riboflavin, 11.0 mg; d-pantothenic 
acid, 22.05 mg; niacin, 33.0 mg; vitamin B12 (as cyanobalamin), 33.0 mg. 
2Trace mineral premix: copper (as CuSO45H2O), 10 mg/kg; iodine (as Ca(IO3) ∙ H2O), 
0.25 mg/kg; iron (as FeSO4 ∙ 2H2O), 125 mg/kg; manganese (MnO), 15 mg/kg; selenium 
(Na2SeO3), 0.3 mg/kg; zinc (ZnSO4 ∙ H2O), 125 mg/kg. 
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Table 1.2. Calculated nutrient composition of diets for Phase 1. 
 
Calculated nutrient composition, % DDGS SRO NS OM 
ME1, kcal/kg 3446 3357 3499 3502 
Crude protein 27.1 25.0 24.8 25.0 
SID2 AA, %         
Arg 1.52 1.48 1.46 1.46 
His 0.60 0.56 0.56 0.56 
Ile 0.95 0.89 0.89 0.89 
Leu 1.96 1.68 1.71 1.72 
Lys 1.51 1.50 1.50 1.50 
Met 0.45 0.45 0.43 0.43 
Met+Cys 0.77 0.76 0.73 0.73 
Phe 1.09 1.00 1.00 1.00 
Phe+Tyr 1.85 1.67 1.66 1.66 
Thr 0.89 0.88 0.89 0.89 
Trp 0.26 0.26 0.25 0.25 
Val 1.06 0.98 0.97 0.97 
STTD3 Phosphorus 0.45 0.45 0.44 0.45 
Total Phosphorus 0.71 0.72 0.72 0.72 
Calcium 0.85 0.85 0.85 0.85 
Fermentable fiber 14.7 12.0 11.2 11.3 
NDF 10.1 7.14 6.27 6.38 
Starch 22.5 27.5 30.9 30.6 
Sugar 7.81 7.85 7.87 7.92 
 
1ME: metabolizable energy 
2STTD: standardized total tract digestible; SID: standard ileal digestibility 
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Table 1.3. Ingredient composition (% as-fed bases) of diets for Phase 2. 
 
Ingredients, % DDGS SRO NS OM 
Corn 36.8 40.7 43.3 44.5 
Soybean meal, Dehulled, Solvent Extracted 38.0 39.0 39.0 39.0 
Fish Meal 0.00 0.00 0.00 0.00 
Corn DDGS, > 6% and < 9% oil 15.0 0.00 0.00 0.00 
Steam-Rolled Oats 0.00 10.0 0.00 0.00 
Nutrisure 0.00 0.00 10.0 0.00 
Oatmeal 0.00 0.00 0.00 10.0 
Dairylac-80 4.00 4.00 1.40 0.14 
Corn Oil 3.00 3.00 3.00 3.00 
Dicalcium Phosphate 1.10 1.35 1.40 1.40 
Coarse Ground Limestone 1.05 0.90 0.80 0.85 
L-Lys-HCl 0.26 0.28 0.30 0.30 
DL-Met 0.04 0.04 0.08 0.08 
L-Thr 0.00 0.06 0.06 0.06 
Sodium Chloride 0.30 0.30 0.30 0.30 
Vitamin Premix1 0.25 0.25 0.25 0.25 
Trace Mineral Premix2 0.15 0.15 0.15 0.15 
 
 
 
1Vitamin premix supplied per kg of diet: vitamin A (as retinyl acetate), 5500 IU; vitamin 
D (as cholecalciferol), 550 IU; vitamin E (as tocopherol acetate), 30 IU; vitamin K (as 
menadione dimethylpyrimidinol bisulfate), 4.4 mg; riboflavin, 11.0 mg; d-pantothenic 
acid, 22.05 mg; niacin, 33.0 mg; vitamin B12 (as cyanobalamin), 33.0 mg. 
2Trace mineral premix: copper (as CuSO45H2O), 10 mg/kg; iodine (as Ca(IO3) ∙ H2O), 
0.25 mg/kg; iron (as FeSO4 ∙ 2H2O), 125 mg/kg; manganese (MnO), 15 mg/kg; selenium 
(Na2SeO3), 0.3 mg/kg; zinc (ZnSO4 ∙ H2O), 125 mg/kg. 
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Table 1.4. Calculated nutrient composition of diets for Phase 2. 
 
Calculated nutrient composition, % DDGS SRO NS OM 
ME1, kcal/kg 3446 3357 3499 3502 
CP 27.1 25.0 24.8 25.0 
SID2 AA, %         
Arg 1.52 1.48 1.46 1.46 
His 0.60 0.56 0.56 0.56 
Ile 0.95 0.89 0.89 0.89 
Leu 1.96 1.68 1.71 1.72 
Lys 1.51 1.50 1.50 1.50 
Met 0.45 0.45 0.43 0.43 
Met+Cys 0.77 0.76 0.73 0.73 
Phe 1.09 1.00 1.00 1.00 
Phe+Tyr 1.85 1.67 1.66 1.66 
Thr 0.89 0.88 0.89 0.89 
Trp 0.26 0.26 0.25 0.25 
Val 1.06 0.98 0.97 0.97 
STTD2 Phosphorus 0.45 0.45 0.44 0.45 
Total Phosphorus 0.71 0.72 0.72 0.72 
Calcium 0.85 0.85 0.85 0.85 
Fermentable fiber 14.7 12.0 11.2 11.3 
NDF 10.1 7.14 6.27 6.38 
Starch 22.6 27.5 30.9 30.6 
Sugar 7.81 7.85 7.87 7.92 
 
1ME: metabolizable energy 
2STTD: standardized total tract digestible; SID: standard ileal digestibility 
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FIGURES 
 
Figure 1.1. Alpha Diversity measures of location samples were extracted (Sampletype) 
compared among diets. 
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Figure 1.2. Relative abundance principal component of analysis plot with variables 
sample type versus diet. 
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Figure 1.3. Phylum composition of sampling site bacterial communities by diet for ID, 
CD, IM, and CM. 
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Figure 1.4. Average daily gain within diet in wk 1-4. 
 
 
 
Figure 1.5. Average daily feed intake within diet in wk 1-4. 
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Figure 1.6. Gain:feed within diet in wk 1-4. 
 
 
 
Figure 1.7. Body weight within diet on d 0, 7, 14, 21, and 28. 
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Chapter 3: Effects of soybean-derived isoflavones on nursery pig growth 
performance, microbiome, and immune parameters. 
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ABSTRACT 
 The effects of soybean-derived isoflavones on the microbiome, growth 
performance, and interleukin-8 (IL-8) were observed in nursery pigs. Sixty-four pigs 
weaned at 21 d were randomly allotted to 16 pens (4 pigs/pen; 4 pens/treatment) with sex 
represented evenly in each pen. Pigs had ad libitum access to feed and water for the 2-
phase nursery period (28 d). Dietary treatments included: 1) Hamlet protein’s HP-300 
(highly digestible soybean meal product), 2) HP-300 + Novasoy 400 (isoflavone 
supplement), 3) Arcon-F (soy protein concentrate in place of soybean meal), and 4) 
Arcon-F + Novasoy 400. Fecal samples were collected on d 0, 14, and 28 (n = 32) as well 
as blood samples for IL-8 enzyme-linked immunofluorescence assay (ELISA) while ileal 
and colonic mucosa and digesta samples were collected solely on d 28 (n = 16) for 
analysis of microbial species using IlluminaTM next generation sequencing. The DNA 
sequences were filtered through the DADA2 pipeline, Mothur, and QIIME. Pig body 
weights and feeder weights were also measured on d 0, 7, 14, 21, and 28 (n = 64) for 
growth performance analysis. There were no differences in growth performance for body 
weight (BW), average daily feed intake (ADFI), average daily gain (ADG), or gain:feed 
(G:F); (P > 0.10). While diet did not affect the amount of circulating IL-8, there was an 
increase in the concentration of blood serum IL-8 over time (P < 0.001). Diet, day, and 
sample location caused differences in microbial composition (P < 0.01) with most 
variation resulting from the Arcon-F diet that had a lower presence of the Chlamydiae, 
Fusobacteria, and Proteobacteria phylums. The composition of bacteria varied over time 
with an increase in Chlamydiae, Vertebrata, Cyanobacteria, and Spirochaetes by d 14 (P 
< 0.001), but these differences were not detected between d 14 and 28. Colonic digesta 
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was the least diverse with a decrease in many phyla, most notably Bacteroidetes, 
Firmicutes, Cyanobacteria, and Actinobacteria (P < 0.005).   
Key words: gastrointestinal microbiota, immunity, isoflavones, nursery piglets 
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INTRODUCTION 
 With the introduction of the Veterinary Feed Directive and consumer demands, 
most producers are moving towards using feed ingredients that improve gut health with 
nutritional intervention in production to amplify the immune system and decrease the use 
of antibiotics. A member of the legume family, soybeans are inexpensive and easily 
processed to a defatted version that is popular to consume for both humans and animals. 
In swine, soybean meal is a common ingredient used for its high protein content and 
digestibility with over 4.06 billion bushels of soybeans produced in the U.S. in 2016 
alone, with numbers increasing annually (Schulz et al., 2016). Once the hulls are 
removed, the soybean oil is extracted and the solvent is removed, the leftover flakes are a 
product high in quality protein content with most anti-nutritional factors removed 
(Johnson et al., 1995). In processed soybean meal, the phytoestrogens classified as 
isoflavones remain intact and retain bioactivity to influence many immune parameters of 
interest. Isoflavones are ingested mainly in their glycosidic form (daidzin, genistin, and 
glycitin) before β-glycosidases that reside in bacteria and the epithelial lining of the host 
cleave the glycosidic groups to their aglycosidic form (daidzein, genistein, and glycitein); 
(Aglin et al., 2013). Resembling estrogen, isoflavones exert either weak estrogenic or 
antagonistic effects conditionally, depending on the age, health status, sex, and the 
composition of the gut microbiome in the host. Genistein and daidzein are the bioactive 
forms formed during digestion from the gut microbiota and cells from zymogens genistin 
and daidzin; however, there is interest in the metabolite equol as it may have enhanced 
estrogenic activity than these two compounds combined (Anupongsanugool et al., 2005). 
Isoflavones are of interest due to their anti-inflammatory, antiviral, and antimicrobial 
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properties as well as in some cases, relieving cancer patients; however, adverse effects in 
cancer patients suggest that there are appropriate situations to use the compounds, 
depending on if the patient has more estrogen receptor (ER) α or β (Russo et al., 2016). 
There is interest to understand which gut microbes are able to digest the isoflavones and 
produce the beneficial metabolites that induce the immune system to increase circulating 
cytokines, maintain a diverse and healthy gut microbiome to combat disease when 
introduced, maintain intestinal epithelial integrity, and positively effect growth 
performance.   
Objective: To determine the effects of isoflavones derived from a soybean meal product 
compared to a soy protein concentrate with low anti-nutritional factors and an isoflavone 
concentrate added to both products (Arcon-F, Arcon-F + Novasoy 400, HP-300, HP-300 
+ Novasoy 400) on nursery pig growth, feed efficiency, gastrointestinal microbiota, and 
interleukin-8.  
 
MATERIALS AND METHODS 
Animals 
Piglets (n = 64; WXL/DNA Genetics Landrace/DNA Genetics Yorkshire x DNA 
Genetics Duroc) were weaned at 21 d of age and allotted to 16 experimental pens with 
equal representation of sex in each pen (n = 4, males = 2, females = 2), similar body 
weight (BW) of 5.5  0.5 kg, and nearly even distribution of litters. Pigs were given ad 
libitum access to feed and water throughout the experiment. All lights in the experimental 
room remained on 24 h/d throughout the duration of the experiment. Room temperature 
was 28 C during wk 1 and dropped by 2 degrees each wk, thereafter heat lamps were 
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used during the first 2 wk to provide extra heat inside the pens. The entire experiment 
lasted for an interval of 28 d and sample collection of feces occurred after pigs were 
positioned in their respective pens on d 0, 14, and 28 from n = 32 pigs and diets were 
randomly assigned. Ileal mucosa (IM), ileal digesta (ID), colonic mucosa (CM), and 
colonic digesta (CD) samples were also obtained on d 28 from n = 16 pigs. Body weight 
and feeder weights were recorded on d 0, 7, 14, 21, and 28 to estimate average daily feed 
intake (ADFI), average daily gain (ADG), and gain:feed (G:F). 
 
Diets 
Four dietary treatments were fed in 2 phases and all diets were similar to a corn-
soybean meal diet formulated to meet nursery pig requirements based on weight (NRC, 
2012). The high bioavailable protein soybean product HP-300 (Hamlet Protein; Findlay, 
OH) and Arcon-F, a soy protein concentrate (ADM; Chicago, IL) were used to replace 
SBM and are referred to as HP-300 and Arcon-F diets, respectively. Diets were also 
formulated with these products combined with Novasoy 400 (ADM; Chicago, IL) to add 
supplemental isoflavones. The 2 diets with extra isoflavones were formulated to contain 
similar inclusions of isoflavones at 2,011 mg/kg and are referred to as HP+NS (HP-300 + 
Novasoy 400) or AF+NS (Arcon-F + Novasoy 400). These inclusions were determined 
by the concentration of isoflavones in a typical soybean meal diet and referencing 
literature that has included isoflavones up to 2,500 mg/kg in the diet while accounting for 
a margin of safety to prevent the deleterious effects. Similar nutrient content was 
maintained among diets within phase with no antibiotics or ZnO. Each diet phase was fed 
    70 
for 2 wk and ingredient inclusion and calculated nutrient composition for each diet and 
phase is illustrated in Tables 2.1-2.4. 
 
Data Collection 
Feed disappearance and individual pig BW were measured weekly for 4 
consecutive weeks post-weaning for the determination of average daily gain (ADG), 
average daily feed intake (ADFI), and gain:feed (G:F). Fecal and blood samples were 
collected on d 0, 14, and 28 from 2 pigs in each pen. Blood samples were analyzed for 
IL-8 concentrations in the serum and feces were used for characterization of the 
microbiome. Pigs (n = 16) were euthanized at the end of the study on d 28 and mucosal 
scrapings, and luminal contents from both the ileum and colon were collected for DNA 
analysis and microbiome composition determination. 
 
DNA Isolation and Sequencing 
A Mag Bind Soil DNA Kit (Omega Bio-tek, Norcross, GA), was used to extract 
DNA from luminal contents and tissue scrapings in both the ileum and the colon as well 
as from fecal samples. The obtained DNA was isolated in a KingFischer Isolation system 
(ThermoFisher Scientific, Waltham, MA) and amplified using polymerase chain reaction 
and profiled for quality and quantity with 1.5% DNA Gel Agarose Electrophoresis. 
Samples were then normalized and purified using an NGS Normalization 96-well kit 
(Norgen Biotek Corp, Thorold, Ontario) and pooled together. Samples were quantified 
with a Denovix kit and reader (DeNovix, Wilmington, DE) and purity assessed with a 
High Sensitivity DNA kit, chip, and Bioanalyzer (Agilent, Santa Clara, CA) to ensure 
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dimers were removed and peak concentrations were high enough. Libraries were found to 
be eligible for a 2 nM sequencing run using a V2 kit with a Next Generation Sequencer 
(Illumina, San Diego, CA).  
 
IL-8 ELISA 
 A DuoSet ELISA Porcine IL-8/CXCL8 kit was used to measure porcine 
Interleukin 8 in serum isolated from blood. All reagents were brought to room 
temperature before use and components were allowed to sit for a minimum of 15 minutes 
with gentile agitation after initial reconstitution. Working dilutions were prepared and 
used immediately, except for the Wash Buffer and Reagent Diluent. The Capture 
Antibody was diluted to working concentration in PBS without the carrier protein and 
immediately used to coat a 96-well microplate, sealed, and incubated overnight at room 
temperature. The next day, wells were aspirated and washed with Wash Buffer 3 times 
using a manifold dispenser. The plate was then blocked with Reagent Diluent and 
incubated at room temperature for at least 1 hour and washed again. The samples were 
then added to the wells in duplicate to enhance reproducibility, covered with an adhesive 
strip, and incubated at room temperature for 2 hours. The plate was then washed before 
the Detection Antibody, diluted in Reagent Diluent and Normal Goat Serum, was added 
to each well, covered with a new adhesive strip, and incubated for 2 hours at room 
temperature. Samples were then washed before a working dilution of Streptavidin-HRP 
was added to each well and incubated for 20 minutes at room temperature while covered 
and out of direct light. The wash step occurred once more before the Substrate Solution 
was added to each well incubated for 20 minutes at room temperature out of direct light. 
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The Stop Solution was then added to each well and the plate was gently tapped to ensure 
thorough mixing before the optical density of each well was determined. The microplate 
reader was set to 450 nm and wavelength correction at 540 nm.  
 
Statistical Analysis 
The DNA analysis began with the filtering of sequence reads as well as trimming 
to remove chimeras that may skew results. An ASV table was generated in R using 
Dada2 and a phylogenetic tree in mothur. The tree was merged with the ASV table in R, 
a mapping file designed for variables of interest was added, and taxa were assigned from 
a Silva taxonomy package. Bray Curtis distances were generated to determine relative 
abundance measures in the MicrobiomeSeq and DESeq2 packages. Amplicon sequence 
variants (ASVs) were used as opposed to OTUs for more accurate analysis. The Adonis 
and Permanova functions included in the Vegan package were used to generate p-values 
to identify locational effects and which taxa were significantly different. R was also used 
to generate principal component of analysis plots from Bray Curtis values as well as 
alpha diversity.  
Growth performance analysis was performed using a 1-way analysis of variance 
(ANOVA) conducted using the MIXED procedure of SAS 9.4 (SAS Inst. Inc., Cary, NC) 
to differentiate treatment effects at a significance level of P ≤ 0.05 and trends at a 
significance level of 0.05 < P < 0.15.  
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RESULTS  
Growth performance 
 Diet did not effect ADG, ADFI, BW, or G:F (P > 0.10). Body weight averaged 
15.20 kg by day 28 with an ADG of 1,276.8 g. There was a decrease in feed intake for all 
pigs receiving diets during wk 4, with wk 3 averaging 1,170 g per diet per day while 
ADFI in wk 4 was only 793 g/d. No differences were observed at specific weeks or 
phases (P  > 0.10); however, there was a trend for G:F to be greater in the Arcon-F + 
Novasoy 400 diet during wk 1 and 3 (P = 0.113). 
 
Microbiome analysis 
 Significant differences in microbial composition and diversity were observed 
among diets, the location the samples were isolated from, and over time. The diets that 
produced significantly different microbial composition were the Arcon-F diet that 
maintained less diversity while the Arcon-F + Novasoy 400 saw an increase in abundance 
of genus’. The AF diet showed an increased abundance of the phyla Chlamydiae, 
Fusobacteria, and Proteobacteria (P < 0.005; Table 2.8). Genus’ that were less abundant 
were Veillonella, Lactobacillus, Christensenella, Lachnospiraceae, Chlamydia, 
Actinobacillus, Sphingomonas, and Bifidobacterium (P < 0.001). At the phylum level, 
AFNS showed an increase in Ruminococcaceae, Syntrophococcus, Allisonella, 
Schwartzia, Sanguibacteroides, Leptotrichia, Slackia, Collinsella, Olsenella, 
Enterococcus, Truicibacter, and Shuttleworthia (P < 0.001)..  
 The microbiome became increasingly diverse over time (P = 0.001) as shown in 
Figure 2.1. After d 0, there was an increase in several genus’ including Euryarchaeota, 
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Verrucomicrobia, Planctomycetes, Synergistetes, Actinobacteria, and Lentispharerae (P 
< 0.001). By d 14, there was a greater abundance of Chlamydiae, Vertebrata, 
Cyanobacteria, Fibrobacteres, Spirochates, Epsilonbacteraeota, Deferribacteres, 
Tenericutes, and Patescibacteria (P < 0.001).  
 Microbial diversity varied between sampling location (P = 0.001) with most of 
the variation occurring in the CD; however, there was variation in the CM, as well. There 
was a decrease in abundance of Blautia, Marvinbryantia, Fusicatenibacter, Dorea, 
Lachnospiraceae, Oribacterium, Dialister, Allisonella, Megasphaera, Mitsuokella, 
Selenomonas, Acidaminococcus, Phascolarctobacterium, Oscillibacter, Anaerofilum, 
Angelakisella, Faecalibacterium, Subdoligranulum, Pygmaiobacter, and Butyricicoccus 
in the CD (P < 0.001). The CM showed an upregulation of Vibrionimonas, 
Sediminibacterium, Chlamydia, Klebsiella, Escherichia Shigella, Mycoplasma, 
Pelomonas, Pseudomonas, Stenotrophomonas, Bradyrhizobium, Methylobacterium, 
Helicobacter, and Bacillus (P < 0.001). Microbial composition of the feces was not 
different from the CD (P > 0.05). 
 The top 10 families responsible for diversity differences included 
Ruminococcaceae, Lachnospiraceae, Shuttleworthia, Allisonella,Slackia, Angelakisella, 
Turicibacter, Clostridium, Veillonella, and Negativabacillus in decreasing order (P < 
0.001). 
 
IL-8 ELISA  
 The IL-8 concentration in blood serum did not change with diet (P > 0.10); 
however, there was an increase in circulating IL-8 over time (P < 0.001), except for in the 
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Arcon-F diet. This diet showed a decrease in IL-8 in the blood serum by d 28 as shown in 
Figure 2.7.  
 
DISCUSSION 
 No differences were observed among diets for growth performance as ADG, 
ADFI, G:F, and BW remained consistent within phase. While there is always an interest 
in using products in diets that cause pigs to perform better than others, growth 
performance in this study cannot be included as a reason for microbiome diversity 
changes and the differences in observations can be reserved strictly for the variables of 
interest, diet, time, and sampling location. 
The differences observed in microbial composition caused by diet were primarily 
in the diets containing the Arcon-F product. The AF diet showed less abundance of many 
bacteria that are typically high in the piglet microbiome. Of these, Veillonella is an early 
colonizer that forms a mutually beneficial relationship with the host through its role in 
lactic acid metabolism (Periasamy et al., 2010). Lactobacillus is also a beneficial 
bacterium that was found in lower abundance, putting these animals at a disadvantage in 
not being able to utilize their health-promoting properties, even though this species does 
not typically colonize in the gut, but is allochthonous (Walter et al., 2008). 
Lachnospiraceae also colonize early and participate in carbohydrate metabolism to 
produce SCFA, energy sources for the microbiome (Sagheddu et al., 2016). Schwartzia is 
another phylum that produces energy for the GIT bacteria using succinate, a common 
metabolite in cellular processes, such as the citric acid cycle (Gylswyk et al., 1997). If the 
colonization of this phylum is inhibited, it’s questionable how efficient these animals will 
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be in production if energy sources are few. Bifidobacterium is also involved in initial 
establishment in the GIT with probiotic actions exerted on the host, especially infants as 
this phylum is attuned to metabolism of milk oligosaccharides (O’Callaghan et al., 2016). 
Christensenella has been shown to be the most heritable of the gut bacteria and is directly 
related to obesity. This phylum has been found in higher abundance in individuals with a 
lower body mass index and combats obesity by decreasing adipose deposits (Madsen et 
al., 2017). The Sphingomonas phylum dwindled in the AF diet as well and has been 
shown to contribute to the immune response by producing glycolipids for natural killer T 
cells that ward off infection (Caballero et al., 2015). From a beneficial standpoint, it was 
observed that there was a downregulation of Chlamydia that resides in the gut as an 
opportunistic pathogen (Rank et al., 2014). Once infection ensues, the immune system is 
unable to clear the Chlamydiae entirely, thus a lower initial presence is desirable. The 
same concepts apply for Actinobacillus, as this phylum has been related to numerous fatal 
diseases and is inactively harbored in the GIT until infection is triggered (Rycroft et al., 
2000). The AFNS diet showed increases in abundance of bacteria more than any other 
diet. Among these phyla was Ruminococcaceae that has been associated with individuals 
that maintain high energy metabolism (Menni et al., 2017). Allisonella has been shown to 
increase insulin resistance and tumor necrosis factor, leading to endotoxemia and small 
intestinal bacterial growth (Catinean et al., 2018). Collinsella was upregulated in the 
AFNS diet and can alter the host bile acids to regulate the virulence and pathogenicity of 
enteric pathogens (Gomez-Arango et al., 2018). Leptotrichia and Enterococcus are other 
opportunistic pathogens that mainly reside in the oral cavity and ferment carbohydrates to 
produce lactic acid in both the mouth and the GIT (Eribe et al., 2008). Species of the 
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genus Slackia that were found in high abundance are known to produce equol from 
isoflavones in the human intestine (Jin et al., 2009). If more equol producing bacteria are 
present where supplemental isoflavones have greater inclusion, there is more opportunity 
for utilization of the metabolites and ability to study the effects. Upregulation of 
Syntrophococcus was observed, a phylum able to metabolize isoflavones and was present 
in the diet containing supplemented isoflavones. These bacteria have been shown to 
participate in O-demethylation of monoaromatic derivatives in the rumen, such as the 
formation of O-DMA (Doré et al., 1990). Greater abundance of isoflavone metabolizing 
microbes was shown in the diet that included supplemental isoflavones, proposing that 
these bacteria will colonize in the microbiome if isoflavones are included in diet in the 
early stages of life.  
 Alpha diversity as shown in Figures 2.1 and 2.3 identifies differences in the 
number of species present in day and sample location; however, there were evidently 
similar numbers of bacteria in diet, as shown in Figure 2.2. Euryarchaeota are of interest 
as they are organisms known to survive in even the most extreme conditions, potentially 
able to thrive when disease occurs (Castro-Fernandez et al., 2017). Planctomycetes, 
Lentispharerae, and Verrucomicrobia that metabolize methane were shown to increase 
over time, highlighting the diversity that increases in the microbiome in even just two 
weeks (Lee et al., 2009). The integrity of the microbiome was enhanced as 
Actinobacteria increased, a prominent member of the gut microbiome that produces 
antibiotics (Ventura et al., 2007), providing a defense mechanism for both the bacteria 
and the host. The microbiome diversity continued to proliferate with more of the 
prominent genus’, such as Cyanobacteria and Fibrobacteres becoming more abundant 
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with the change from the phase 1 to phase 2 diets. Fibrobacteres participates in cellulose 
metabolism and as more fiber was included in the diet, the more opportunity for this 
genus to thrive (Ransom-Jones et al., 2012). The increase of Chlamydiae showed that 
beneficial bacteria weren’t the only ones able to colonize, as this opportunistic pathogen 
was able to gain access to the GIT and find it’s niche (Rank et al., 2014). 
Epsilonbacteraeota have been shown to be early colonizers in previous studies (Methou 
et al., 2019) as symbiotic bacteria, observations verified with the indication of high 
abundance in the nursery phase of piglets. There was an upsurge of 
Epsilonproteobacteria, Patescibacteria, and Deferribacteres, genus’ known for the 
utilization of iron and reduction of nitrate (Gittel et al., 2012), showing how the microbes 
are able to break down more material in the gut as more bacteria colonize. Tenericutes 
further shows the increase in diversity by being one of the few bacteria that do not 
possess a peptidoglycan cell wall (Skennerton et al., 2016). An increase in the abundance 
and diversity of these vastly different bacteria represent how much the microbiome can 
develop in a short time period. 
Sample location was shown to affect microbial composition, especially in the 
colon where luminal contents were much less diverse than colonic mucosa. In the digesta, 
there were many genus’s accounted for that were in less abundance, including both 
beneficial and pathogenic bacteria. It is understandable that more bacteria are present in 
the lining, the greater opportunity for colonization compared to the digesta that is 
constantly moving through the GIT until it is expelled from the body, thus bacteria must 
constantly be competing for a spot in the lining to maintain their niche and stay in the 
body. Some of the bacteria in the digesta could be present only due to the sloughing of 
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the intestinal walls that force them into the lumen. It is worth nothing that the fecal 
samples were similar to the colonic digesta samples, thus feces may be used for microbial 
analysis of the colonic digesta that uses a less invasive method for collection.  
IL-8 circulating in the blood serum was not different among diets; however, it did 
increase over time. Studies have shown that as mammals mature, their immune systems 
are more suited to focus on stimulating factors that give the organism an advantage 
against potential pathogens by promoting synthesis and secretion of cytokines 
(Carstensen et al., 2010). While IL-8 may not have been mobilized with the inclusion of 
isoflavones, other cytokines and TNF-α concentrations would be of interest, because only 
1 cytokine does not mean an increase or decrease in gut health or immunity.  
 
CONCLUSION 
 There were no differences in growth performance or circulating IL-8 among diet 
(P > 0.10) for this experiment; however, there is evidence that diet, time, and location of 
sample extraction all affect the gut microbiome composition. Arcon-F, the diet with 
essentially no inclusion of isoflavones decreased in microbial diversity compared to the 
other diets (P < 0.001), while the Arcon-F + Novasoy 400 diet had greater concentrations 
of notable bacterium, including those that can metabolize isoflavones into equol (P  < 
0.01). The HP-300 and HP-300 + Novasoy 400 diets did not show any significant 
differences within this threshold of analysis. Between d 0 and 14 of the experiment, there 
was a shift in the microbiota with significant changes even in the first phase as a result of 
the switch in diet (P < 0.001). This suggests that the microbiome is easily affected during 
the first stages of life and is rapidly changing during this time with the introduction of 
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new feed and/or a new environment. The location in the gastrointestinal tract has varying 
microbial composition as well, as mucosa and digesta samples differ considerably (P < 
0.05). However, feces and colonic digesta are close enough in composition that if one is 
interested in CD microbial structure, taking fecal samples will suffice as a less invasive 
method. A decrease in beneficial bacteria in the GIT of pigs fed soy protein concentrate 
diet with no isoflavones suggests that some species of bacteria thrive off of the 
phytoestrogens and other compounds typically found in SBM that are removed during 
processing. These bacteria may be involved in gut barrier function and integrity. Further 
experimentation should take place with a disease challenge where piglets are infected 
with a pathogen after ingesting varying doses of isoflavones and immune parameters and 
the microbiome again analyzed. 
 
IMPLICATIONS 
 During wk 4, there was a decrease in ADFI and ADG compared to wk 3. This is 
not typical to experimentation as growth and feed intake usually only increase the with 
the duration of the experiment. There could also be upregulation or downregulation of 
bacteria in the diets that were not included in the top 10 families; however, our analysis 
only included those families most prominent.  
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TABLES 
Table 2.1. Ingredient composition (% as-fed bases) and calculated nutrient composition 
of diets for Phase 1. 
 Diets 
 HP-300 
HP-300 + 
Novasoy 400 Arcon-F 
Arcon-F + 
Novasoy 400 
Ingredients, %     
Corn 42.3 41.9 42.5 41.9 
Dicalcium phosphate, 
18.5% P 1.05 1.05 1.10 1.10 
Limestone 1.07 1.07 1.00 1.00 
Salt 0.10 0.10 0.10 0.10 
Vitamin premix1 0.25 0.25 0.25 0.25 
Trace mineral premix2 0.15 0.15 0.15 0.15 
Corn Oil 3.00 3.00 3.00 3.00 
Lysine·HCl 0.45 0.45 0.21 0.21 
DL-Methionine 0.14 0.14 0.32 0.32 
L-Threonine 0.11 0.11 0.02 0.02 
Whey, dried 15.2 15.2 15.2 15.2 
Dairylac-80 11.3 11.3 11.3 11.3 
HP-300 25.0 25.0 0.00 0.00 
Novasoy 400 0.00 0.35 0.00 0.50 
Arcon-F 0.00 0.00 25.0 25.0 
Calculated nutrient 
composition, %   
 
 
Crude protein 29.7 29.7 22.5 22.5 
ME (kcal/kg)3 3530 3518 3037 3037 
Ca 0.80 0.80 0.80 0.80 
STTD4 P 0.40 0.40 0.40 0.40 
SID4 Lys 1.35 1.35 1.36 1.36 
SID Met 0.40 0.40 0.40 0.40 
SIDl Thr 0.79 0.80 0.80 0.80 
SID Trp 0.23 0.23 0.23 0.23 
Total Lysine 1.48 1.48 1.40 1.40 
Total Phosphorus 0.62 0.61 0.62 0.62 
Ca:P 1.29 1.31 1.29 1.29 
Isoflavones (mg/kg) 604 2011 0 2011 
1Vitamin premix supplied per kg of diet: vitamin A (as retinyl acetate), 5500 IU; vitamin D (as 
cholecalciferol), 550 IU; vitamin E (as tocopherol acetate), 30 IU; vitamin K (as menadione 
dimethylpyrimidinol bisulfate), 4.4 mg; riboflavin, 11.0 mg; d-pantothenic acid, 22.05 mg; niacin, 33.0 mg; 
vitamin B12 (as cyanobalamin), 33.0 mg. 
2Trace mineral premix: copper (as CuSO45H2O), 10 mg/kg; iodine (as Ca(IO3) ∙ H2O), 0.25 mg/kg; iron (as 
FeSO4 ∙ 2H2O), 125 mg/kg; manganese (MnO), 15 mg/kg; selenium (Na2SeO3), 0.3 mg/kg; zinc (ZnSO4 ∙ 
H2O), 125 mg/kg. 
3ME: metabolizable energy  
4STTD: standardized total tract digestible; SID: standard ileal digestibility 
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Table 2.2. Ingredient composition (% as-fed bases) and calculated nutrient composition 
of diets for Phase 2. 
 Diets 
  HP-300 
HP-300 + 
Novasoy 400 Arcon-F 
Arcon-F + 
Novasoy 
400 
Ingredients, %     
Corn 45.7 45.3 45.9 45.4 
Dicalcium phosphate, 18.5% 
P 0.70 0.70 0.70 0.70 
Limestone 1.07 1.07 1.00 1.00 
Salt 0.10 0.10 0.10 0.10 
Vitamin premix1 0.25 0.25 0.25 0.25 
Trace mineral premix2 0.15 0.15 0.15 0.15 
Corn Oil 3.00 3.00 3.00 3.00 
Lysine·HCl 0.41 0.41 0.20 0.20 
DL-Methionine 0.13 0.13 0.28 0.28 
L-Threonine 0.11 0.11 0.02 0.02 
Whey, dried 15.2 15.2 15.2 15.2 
Dairylac-80 11.3 11.3 11.3 11.3 
HP-300 22.0 22.0 0.00 0.00 
Novasoy 400 0.00 0.37 0.00 0.50 
Arcon-F 0.00 0.00 22.0 22.0 
Calculated nutrient 
composition, %     
Crude protein 27.1 27.1 20.8 20.8 
ME3, kcal/kg 3536 3524 3103 3103 
Ca 0.70 0.70 0.70 0.70 
STTD4 P 0.33 0.33 0.33 0.33 
SID4 Lys 1.24 1.23 1.24 1.24 
SID Met 0.37 0.37 0.36 0.36 
SIDl Thr 0.74 0.74 0.74 0.74 
SID Trp 0.20 0.20 0.21 0.21 
Total Lysine 1.37 1.35 1.36 1.36 
Total Phosphorus 0.55 0.53 0.53 0.53 
Ca:P 1.27 1.32 1.32 1.32 
Isoflavones (mg/kg) 532 2019 0 2019 
 
1Vitamin premix supplied per kg of diet: vitamin A (as retinyl acetate), 5500 IU; vitamin D (as 
cholecalciferol), 550 IU; vitamin E (as tocopherol acetate), 30 IU; vitamin K (as menadione 
dimethylpyrimidinol bisulfate), 4.4 mg; riboflavin, 11.0 mg; d-pantothenic acid, 22.05 mg; niacin, 33.0 mg; 
vitamin B12 (as cyanobalamin), 33.0 mg. 
2Trace mineral premix: copper (as CuSO45H2O), 10 mg/kg; iodine (as Ca(IO3) ∙ H2O), 0.25 mg/kg; iron (as 
FeSO4 ∙ 2H2O), 125 mg/kg; manganese (MnO), 15 mg/kg; selenium (Na2SeO3), 0.3 mg/kg; zinc (ZnSO4 ∙ 
H2O), 125 mg/kg. 
3ME: metabolizable energy  
4STTD: standardized total tract digestible; SID: standard ileal digestibility 
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FIGURES 
Figure 2.1. Bacterial alpha diversity over time for days 0, 14, and 28. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Richness: the number of species per sample; The more species present in a sample, the 'richer' the sample. 
Simpson alpha diversity index: the number of organisms of a particular species (n) over the total number of 
organisms of all species (N) subtracted from 1. 
 
 
 
Shannon diversity index: the calculated proportion of species i relative to the total number of species (pi), 
multiplied by the natural logarithm of this proportion (lnpi), multiplied by -1. 
 
(*) = (P < 0.05) 
*
*
*
*
*
Richness Simpson Shannon
D
0
D
1
4
D
2
8
D
0
D
1
4
D
2
8
D
0
D
1
4
D
2
8
0
2
4
6
0.3
0.6
0.9
1.2
10
20
Groups
O
b
s
e
rv
e
d
 V
a
lu
e
s
Day
D0
D14
D28
Bacterial Alpha Diversity by Sample Day
    89 
Figure 2.2. Bacterial alpha diversity for overall experimental diets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Richness: the number of species per sample; The more species present in a sample, the 'richer' the sample. 
Simpson alpha diversity index: the number of organisms of a particular species (n) over the total number of 
organisms of all species (N) subtracted from 1. 
 
 
Shannon diversity index: the calculated proportion of species i relative to the total number of species (pi), 
multiplied by the natural logarithm of this proportion (lnpi), multiplied by -1. 
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Figure 2.3. Bacterial alpha diversity compared between sample locations (SampleType). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Richness: the number of species per sample; The more species present in a sample, the 'richer' the sample. 
Simpson alpha diversity index: the number of organisms of a particular species (n) over the total number of 
organisms of all species (N) subtracted from 1. 
 
 
 
Shannon diversity index: the calculated proportion of species i relative to the total number of species (pi), 
multiplied by the natural logarithm of this proportion (lnpi), multiplied by -1. 
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Figure 2.4. Principal Component of Analysis plot for time of sample collection versus 
diet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Principal Component of Analysis plot for time of sample collection versus 
location of sample. 
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Figure 2.6. Principal Component of Analysis plot for diet versus location of sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: ELISA results of diet over time in pg/mL.  
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Figure 2.8. Phylum composition of sampling site bacterial communities as shown within 
diet. 
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Figure 2.9. Top 10 species diversity in diets.  
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Figure 2.10. Average daily gain within diet in wk 1-4, phase 1-2, and overall. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11. Average daily feed intake within diet in wk 1-4, phase 1-2, and overall. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-400
-200
0
200
400
600
800
1000
1200
1400
1600
1800
Week 1 Week 2 Week 3 Week 4 Phase 1 Phase 2 Total
A
D
G
, g
ARCON AF AFNS HP-300 HPNS TOTAL
-500
0
500
1000
1500
2000
2500
3000
Week 1 Week 2 Week 3 Week 4 Phase 1 Phase 2 Total
A
D
FI
, g
ARCON AF AFNS HP-300 HPNS TOTAL
    96 
Figure 2.12. Gain:feed within diet in wk 1-4, phase 1-2, and overall. 
 
 
 
 
Figure 2.13. Body weight within diet on d 0, 7, 14, 21, and 28. 
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Chapter 4: Determination of immune responses in an intestinal epithelial cell line 
treated with varying doses of genistein and the individual isoflavones. 
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ABSTRACT 
 Two experiments were conducted where IPEC-J2 cells were treated with varying 
concentrations of the isoflavone genistein or similar concentration of each of the 
isoflavones genistin, genistein, daidzin, and daidzein. In the first experiment, cells were 
split into 12 6-well plates with 50,000 cells per well in transmembrane wells and treated 
with varying concentrations of genistein (0, 50, 150, and 300 M), lipopolysaccharides 
(LPS), or polyinosinic:polycytidylic acid (poly I:C). In the second experiment, cells were 
split into 12 6-well plates with 75,000 cells per well and treated with individual 
isoflavones at a concentration of 50 M, while poly I:C was included as well as 
diclofenac sodium salt. In both experiments, media was extracted from the basolateral 
membrane (BLM) and apical membrane (AM) for IL-8 ELISA analysis after plates were 
incubated at 37 C and 5% CO2 at hours 0, 3, 6, and 12. Transepithelial electrical 
resistance (TEER) was measured on the plates that were used for hour 12 collection of 
media. In Exp. 1, treatment did not cause a difference in IL-8 (P > 0.10), but there was an 
increase in IL-8 present in the media with time (P < 0.001) and between BLM and AM (P 
< 0.005). Treatment did cause differences in Exp. 2 (P = 0.0186) where poly I:C secreted 
more IL-8 overall and daidzin was the most anti-inflammatory isoflavone in this 
experiment, suggesting that it is rapidly converted into daidzein in the intestinal 
membrane.  
  In both Exp. 1 and 2, there were no differences for overall TEER (P > 0.10). In 
Exp 1., LPS produced a greater epithelial resistance by hour 12 (P = 0.014) than the other 
treatments. The genistein treatments did not produce greater TEER than LPS; however, 
all 3 genistein treatments averaged greater TEER than poly I:C and 0 M. The 50 M 
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genistein treatment had greater TEER and IL-8 secretion than 150 or 300 M, thus this 
concentration was used in Exp. 2 to for optimize membrane integrity. In both 
experiments, more IL-8 was secreted into the BLM, which simulates the barrier between 
the enterocytes and the blood (P < 0.01). In both experiments, there was an increase in 
IL-8 secretion over time (P < 0.05), imitating production of the chemokine in the GIT. It 
was determined that 50 M of isoflavones is an adequate concentration to treat cells with 
for immune studies. In Exp. 2, the isoflavones did not produce as great of concentration 
of IL-8 as the poly I:C, suggesting that they prevent inflammatory responses from 
occurring. They also did not degrade the epithelial lining to the point of dysfunctionality 
and thus may be used in IPEC-J2 cell line experiments. 
Key words: genistein, interleukin-8, IPEC-J2, transepithelial electrical resistance 
 
 
 
 
 
 
 
 
 
 
 
 
    100 
INTRODUCTION 
 Soy as a protein source is becoming increasingly popular in Western diets due to 
the discovery of numerous benefits associated with the high soy content in Asian diets. 
Soybean meal is a popular protein source in swine diets due to low cost and high 
digestibility. In soy, estrogen-shaped compounds known as isoflavones are found as 
daidzin, genistin, and glycitin, the glycosidic forms (Izumi et al., 2000). Isoflavones have 
been shown to influence immune parameters in mammals; however, the appropriate 
composition of the gut microbiome is required to produce the desired metabolites that 
elicit such responses. Found in soy, isoflavones are still commonly considered to be anti-
nutritional factors because they have been shown to increase cell proliferation in some 
cases, causing quicker progression of some cancers (Khan et al., 2012). Daidzein and 
genistein are the active forms that are cleaved in the gastrointestinal tract from their 
glycosidic forms, daidzin and genistin, by β-glycosidases (Yu et al., 2016). Isoflavones 
have been proven to impact immunity and influence the concentration of circulating 
cytokines in the blood while influencing gut barrier function and membrane integrity 
(Gilbert et al., 2013). Genistein has been proven to retain antiviral, anti-inflammatory, 
and antimicrobial properties and is known as the bioactive isoflavone (Chinta et al., 
2012). Structurally similar to estrogen, genistein exerts estrogenic and anti-estrogenic 
activity on the host. While many characteristics of genistein are desirable, studies have 
shown either drastic upregulation or downregulation of cell proliferation in incidences 
that either damage crypt cells in the jejunum or increase proliferation to the point that 
cancer occurs (Dong et al., 2010). Daidzein forms the metabolite S-equol that is more 
estrogenic and a more potent antioxidant than daidzein that binds to estrogen receptors 
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with more affinity (Kobayashi et al., 2013). To better understand how to take advantage 
of the anti-inflammatory, antiviral, and antimicrobial properties that have been found in 
some cases, research must take place to determine the mechanisms of immune responses 
elicited by the isoflavones individually and as a mixture. It has been reported that 
isoflavones are involved in interactions that enrich the immune response (Yu et al., 
2016); however, individual isoflavone responses should be characterized first to 
understand the contribution that each makes to the innate immune system. IPEC-J2 cells 
are a non-transformed epithelial cell line cultured from the jejunum of an unsuckled 
neonatal piglet. These cells are ideal to measure membrane integrity and cytokine 
production before introducing to a live animal (Brosnahan et al., 2012). These cells 
mimic the intestinal wall lining when cultured in transmembrane well inserts, including a 
basolateral membrane side (BLM) that represents the barrier between enterocytes and the 
blood, while the apical membrane (AM) symbolizes the membrane between the cells and 
the lumen (Chopra et al., 2010). The innate immune system will secrete pro-
inflammatory and anti-inflammatory cytokines into both the BLM and AM, and IPEC-J2 
cells have been found to secrete both into the media on either side of the transmembrane 
well insert. They are capable of being models for the intestinal lining as they are robust 
cells that can maintain function up to 100 passages and still produce immune responses 
when treated with compounds of interest, such as genistein (Vergauwen et al., 2015). 
There are typical concentrations of genistein in products such as soy-based infant 
formulas and soybean meal; however, supplementation of excess isoflavones, including 
genistein, is of interest and determination of the threshold appropriate to include is still 
being researched. In order to harness the benefits without experiencing the adverse 
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effects of isoflavones, different doses of isoflavones both individually and mixed must be 
explored. The IPEC-J2 cell line is useful for determination of maximum and minimum 
treatment exposure while using a more cost-effective method than an in vivo trial, first.  
Objective: To determine the appropriate concentration of genistein to use as a baseline in 
cell culture experiments with IPEC-J2 cells and other isoflavones while maintaining 
intestinal integrity through measurements of cytokine production and transepithelial 
electrical resistance to rationalize use of treatments in further research, including disease 
challenges and observing the immune effects of other isoflavones.   
 
 
MATERIALS AND METHODS 
 
Cell culture 
 IPEC-J2 cells were brought to confluency in two 75 cm2 flasks and split into n = 
12 6-well plates with 0.4 μm pore transmembrane well cell culture inserts (Falcon, 
Corning, NY) in a density of 50,000 cells per well in Exp. 1 and 75,000 cells in Exp. 2. 
Cells were brought to ≥95% confluency before media was aspirated, washed with PBS, 
and treated for 1 hour with the designated treatments. Once the hour was over, media was 
again aspirated and cells were washed with PBS before being cultured with a 1:1 ratio of 
Dulbecco’s Modified Eagle Medium (ThermoFischer Scientific, Waltham, MA) and 
Ham’s F-12 Nutrient Mixture (Gibco, ThermoFischer Scientific, Waltham, MA), 10% 
fetal bovine serum (FBS), 10 L/ 2.0 L epidermal growth factor (EGF), 1% 
penicillin/streptomycin, and 1% insulin/transferrin/Na selenite media supplement.  
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Treatments 
 In Exp. 1, cells were treated with 4 concentrations of genistein (from Glycine 
max, soybean, ~98% HPLC, Sigma-Aldrich, St. Louis, MO)  at 0, 50, 150, or 300 M. 
These treatments were determined by the average concentration of isoflavones in a 
typical soybean meal diet commonly used in the industry and supplementation up to 6 
times the normal dose. These concentrations have commonly been found to lie within a 
margin of safety where the deleterious effects of isoflavones do not normally occur. The 
remaining cells were exposed to either 10 ng/L lipopolysaccharides (LPS) or 20 g/mL 
polyinosinic:polycytidylic acid (poly I:C). The 0 M treatment was used as a control 
while LPS and poly I:C were used as negative controls since they are known to elicit 
innate immune system responses and possess pro-inflammatory properties. In Exp. 2, 
cells were treated with 50 M of either genistein (from Glycine max, soybean, ~98% 
HPLC), genistin (from Glycine max, soybean, 95% HPLC), daidzein (98%, synthetic), 
and daidzin (95% HPLC) (Sigma-Aldrich, St. Louis, MO). Cells were also treated with 
0.2 mM diclofenac sodium salt as a positive control. 20 g/mL polyinosinic:polycytidylic 
acid (poly I:C) was used as a negative control in the final well of the 6-well plate. 
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) and is appropriate to use 
as a positive control while poly I:C was used as a negative control as it produces pro-
inflammatory cytokines in a natural setting. 
 
Sample collection and analysis 
Samples were collected at hours 0, 3, 6, and 12 from 3 plates in the BLM and AM 
while TEER was measured in the 3 plates that were used through hour 12. TEER was 
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measured using an EVOM2 Epithelial Voltohmmeter (World Precision Instruments, 
Sarasota, FL) with STX2 chopstick electrodes. The electrodes were placed on each side 
of the well insert membrane and measured in ohms. Samples were stored in 1.5 mL 
microcentrifuge tubes at -20 C until used for ELISA. A Human IL-8/CXCL8 DuoSet 
ELISA and DuoSet ELISA Ancillary Reagent Kit 2 were used on samples that were 
plated in duplicate to enhance reproducibility and ensure accuracy of the spectrometer. A 
FLUOstar Omega microplate spectrometer was used to determine concentration of IL-8 
in the wells in picograms/microliter. Both IL-8 and TEER values were analyzed for 
differences using a repeated measures analysis of variance (ANOVA) for TEER and one-
way ANOVA for IL-8 in R (R studio, 3.6.0, The R Project) to differentiate treatment 
effects at a significance level of P ≤ 0.05 and trends between 0.05 < P > 0.15. 
 
IL-8 ELISA 
 A DuoSet ELISA Porcine IL-8/CXCL8 kit was used to measure porcine 
Interleukin 8 in serum isolated from blood. All reagents were brought to room 
temperature before use and components were allowed to sit for a minimum of 15 minutes 
with gentile agitation after initial reconstitution. Working dilutions were prepared and 
used immediately, except for the Wash Buffer and Reagent Diluent. The Capture 
Antibody was diluted to working concentration in PBS without the carrier protein and 
immediately used to coat a 96-well microplate, sealed, and incubated overnight at room 
temperature. The next day, wells were aspirated and washed with Wash Buffer 3 times 
using a manifold dispenser. The plate was then blocked with Reagent Diluent and 
incubated at room temperature for at least 1 hour and washed again. The samples were 
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then added to the wells in duplicate to enhance reproducibility, covered with an adhesive 
strip, and incubated at room temperature for 2 hours. The plate was then washed before 
the Detection Antibody, diluted in Reagent Diluent and Normal Goat Serum, was added 
to each well, covered with a new adhesive strip, and incubated for 2 hours at room 
temperature. Samples were then washed before a working dilution of Streptavidin-HRP 
was added to each well and incubated for 20 minutes at room temperature while covered 
and out of direct light. The wash step occurred once more before the Substrate Solution 
was added to each well incubated for 20 minutes at room temperature out of direct light. 
The Stop Solution was then added to each well and the plate was gently tapped to ensure 
thorough mixing before the optical density of each well was determined. The microplate 
reader was set to 450 nm and wavelength correction at 540 nm.  
 
RESULTS 
Interleukin-8 
 In Exp 1., IL-8 did not differ between treatments (P > 0.10); however, secretion of  
IL-8 overall increased over time (P < 0.001) as shown in Figure 4.1. There was also a 
greater concentration of IL-8 secretion in the BLM when compared to the AM (P < 
0.001).  
In Exp. 2, the poly I:C treatment produced the greatest secretion of IL-8 of the 
treatments (P = 0.0186) while daidzin stimulated the least amount of release, as shown in 
Figure 5.1. The more that time went on, the more IL-8 that was released into the media 
with the greatest increase in cytokine production taking place between hours 6 and 12 (P 
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< 0.001). There was an increase in the concentration of IL-8 as samples were taken from 
the basolateral membrane (P = 0.016).  
 
 
 
Transepithelial electrical resistance 
 In Exp. 1, TEER proved to vary both among treatments and over time. LPS 
produced greater membrane integrity (P = 0.0137) than the other treatments, while 150 
M of genistein produced the lowest. Intestinal integrity increased considerably over 
time (P = 0.0107) with the 6-hour time interval between hours 6 and 12 showing a 
dramatic increase in ohms. 
 In Exp. 2, there was not a difference in TEER among treatments (P > 0.10), nor 
were there any differences over time (P > 0.10). This is illustrated in Figure 5.2 where the 
electrical resistance is measured and represented in ohms against time samples were 
collected on hours 0, 3, 6, and 12. 
 
DISCUSSION 
 Genistein did not prove to be more proactive in IL-8 secretion than the LPS; 
however, it was also not lower than the 0 M control or poly I:C negative control. There 
were not statistically significant differences between treatments; however, Figure 4.2 
shows that LPS increased substantially faster than the other treatments if more time was 
allowed with the 50 M genistein treatment closely behind. 50 M genistein produced 
better IL-8 secretion in the BLM and AM compared to 150 M and 300 M, suggesting 
that a lower concentration more closely related to genistein concentrations in industry 
products should suffice for further in vitro analysis without degrading the cells. BLM had 
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more IL-8 secretion than AM as expected, reaffirming that this cell line is useful in 
determining how the concentrations of cytokines released into the blood circulation 
operate instead of being wasted in the lumen. The LPS treatment was greater in TEER 
while 50 M genistein was its closest competitor. With this concentration of genistein 
producing better immune responses than the general control or negative control, it can be 
concluded as an appropriate dosage of genistein to use in this model for further analysis 
of other individual isoflavones, as well as a disease challenge.  
Individual isoflavones did not induce a more prominent innate immune response 
than the negative control, poly I:C, or the positive control, diclofenac. While this may 
seem contradictory, poly I:C is, in general, an immunostimulant and has been proven to 
stimulate chemokines in a manner similar to lipopolysaccharides (LPS) which is 
commonly used as a negative control. While it is unclear why that scenario occurred in 
this trial, the number of studies that observed similar outcomes ensure that poly I:C is not 
exclusively a pro-inflammatory cytokine producer. The isoflavones caused less IL-8 
secretion, suggesting a lower stimulation of inflammatory compounds while potentially 
exerting an anti-inflammatory effect. There were no differences in TEER for treatment or 
time, while time is typically seen to increase epithelial integrity. This could differ in this 
trial from the cells having been seeded into the wells heavier and given 5 days instead of 
7 to become confluent and start building integrity on the transmembrane cell culture 
insert. There was no difference caused by treatment either, which is reassuring that the 
isoflavones may be cultured individually on these cells without degrading them.  
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CONCLUSION 
 Genistein in concentrations 150 and 300 M did not produce a greater innate 
immune response than LPS; however, 50 M of genistein was second best and still above 
the control and negative control responses. There were no overall significant differences 
in treatment for IL-8 (P > 0.10); however, IL-8 secretion was significantly higher in the 
BLM (P < 0.001) and increased over time (P < 0.001). Treatment with LPS caused the 
cells to have greater TEER (P = 0.0137) which gradually increased with time (P = 
0.0107) with the most drastic change between hours 6 and 12. Genistein in a 50 M 
concentration is sufficient for further cell culture experimentation while minimizing cost. 
The remaining isoflavones should be tested at this concentration compared to genistein; 
however, it is important to note that genistein is the bioactive isoflavone and a mixture of 
isoflavones should be tested as well to look for interactions.  
The individual isoflavones secreted less IL-8 than the controls did, suggesting that 
a general control should be used during further experimentation to ensure that they still 
are producing a positive immune response. There was an increase in IL-8 from each 
treatment over time, which agrees with our previous experiment. While there wasn’t a 
large difference observed in IL-8 concentrations among the controls in this experiment, it 
gives reason to believe that isoflavones can be cultured on IPEC-J2 cells safely. This 
gives way to future experiments that can include how cells treated with isoflavones and 
infected with a pathogen compare to cells treated with isoflavones that have not 
undergone infection. The TEER results support this statement because there wasn’t an 
increase in intestinal integrity, nor was there a decrease. Another factor of interest in 
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future studies could be the regulation of MUC-2, the prominent mucin producing gene in 
cells that could explain how mucosal lining is affected, as well. 
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FIGURES 
 
 
Figure 4.1. IL-8 concentrations in the BLM and AM in Exp. 1 over time expressed as 
picograms/microliter.  
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Figure 4.2. IL-8 concentration in the BLM over time in Exp. 1 expressed as 
picograms/microliter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. IL-8 concentration in the AM over time in Exp. 1 expressed as 
picograms/microliter.  
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Figure 4.4. Transepithelial electrical resistance of treatments over time in Exp. 1.  
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Figure 4.5. IL-8 concentrations in the BLM and AM in Exp. 2 over time expressed as 
picograms/microliter.  
 
 
 
 
Figure 4.6. IL-8 concentration in the BLM over time in Exp. 2 expressed as 
picograms/microliter.  
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Figure 4.7. IL-8 concentration in the AM over time in Exp. 2 expressed as 
picograms/microliter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Transepithelial electrical resistance of treatments over time in Exp. 2. 
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ASV Comparison Between Chapter 2 and Chapter 3 
 When comparing microbiome studies, amplicon sequence variants (ASVs) are 
commonly used for their reusability, reproducibility, and resolution. In order to establish 
a baseline microbiome for nursery piglets, metanalysis of studies that sequence GIT 
samples are possible through the use of ASVs instead of operational taxonomic units 
because the variation and errors in the DNA sequence are able to be traced to the location 
of the base pairs. The microbiome data from chapters 2 and 3 were merged and analyzed 
using simper, a function of the vegan package in R. This function discriminates species 
using Bray Curtis dissimilarities and displays the most important species for each group 
that contribute to at least 70% of the differences between variables.  
 In chapters 2 and 3, diets were compared and a few bacteria causing differences 
were Prevotella, Clostridium, Lactobacillus, and Ruminococcaceae with most variance 
occurring as a result of the Prevotella abundance. As previously mentioned, Prevotella is 
the most abundant species in the adult GIT and it would be of interest to determine which 
diets contributed to colonization for this species and why it is the most abundant. 
Clostridium is a prominent butyrate producer, ferments amino acids, and is found in 
higher abundance in those individuals that are able to produce equol. The comparisons 
could be done to determine if the diets containing a greater inclusion of isoflavones do 
have a greater presence of this bacteria. Lactobacillus is commonly found in probiotics 
and assists in carbohydrate fermentation. Chapter 2 explores the effects of varying 
carbohydrate sources on the microbiome and one or all of these diets could cause greater 
colonization when compared to chapter 3. Ruminococcaceae caused the most variation in 
microbial composition in chapter 3 and is a common carbohydrate fermenter. There 
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appears to have been a difference in carbohydrate fermentation among the two studies 
when analyzing diets. More analysis should be done to determine if the piglets ingesting 
the varying carbohydrate sources will be more adept to ferment carbohydrates based on 
the colonization of the species containing the carbohydrate active enzymes. 
Sampling location was compared among the studies and it has already been 
determined that microbial composition varies significantly based on the location the 
samples were isolated from in both chapters 2 and 3. Again, Prevotella was the most 
prominent species for producing differences, telling that not only does diet affect 
colonization, but this bacterium is colonizing in one section of the GIT more than the 
other. Ruminococcaceae and the uncultured Anaerorhabdus bacterium were at the top of 
the list for variation. Ruminococcaceae, like Prevotella, suggests that diet affects the 
colonization in various parts of the GIT. The presence of Anaerorhabdus reminds 
researchers that there is still much to learn about the structure and function of the 
gastrointestinal microbiome, but that we are getting closer. 
The microbial composition over time was analyzed and Prevotella was the 
bacteria that accounted for the most variation. It is again, the most abundant species in 
the adult, and the observation that the abundance is changing over time in a nursery piglet 
is not surprising. Oscillibacter, a species known to cause bacterium, fluctuated with time, 
possibly either by the reduction of the species over time after the piglets recover from the 
weaning stress, or possibly colonizes more over time as each bacterium establishes its 
niche in the GIT. The abundance of Roseburia also varied with time; however, this 
species is a commensal bacteria that produces SCFA, especially butyrate, giving it 
potential to act as a marker of health or serve as a biomarker for symptomatic 
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pathologies, such as the formation of gallstones. While there are many species that 
account for differences over time, the diversity of these three account for the theory that 
the immune system is gradually becoming stronger with the colonization of certain 
microbes; however, the interaction of the GIT microbiota within itself and with the host 
could cause functional differences and contributions. 
Merging ASVs allows for the reproducibility of studies to be accounted for in 
research while also contributing to the discovery of microbial composition, the similar 
species among trials, and which variables (day, diet, sampling location, etc.) cause 
diversity differences. The contribution of each microbiome trial to a greater study will 
allow a core microbiome to eventually be established and perhaps even allow individual 
studies to compare microbial sequences to a large database to determine the differences 
of their own study to the “norm” and make it easier to locate which bacteria are not 
typically found in the pig microbiome, but were abundant in their trial. While 
composition is important, there must also be more research to determine the function of 
each of the microbial species because just knowing that a species is abundant does not 
provide researchers with the information of what that actually means for the structure and 
function of the GIT and what those microbes contribute to the host. Merging these two 
ASVs is a start for determining microbial similarities in the nursery piglet and is just a 
fraction of what might soon contribute to a core piglet microbiome.  
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APPENDIX 
 
DNA Extraction and Sequencing Protocol 
DNA Extraction 
 
Kit: Mag Bind Soil DNA kit. 4 x96 preps (Omega) 
 
Set watch bath/incubator to 90˚C 
Heat elution buffer to 70˚C- optional 
Prepare ice bucket 
Chill centrifuge to 4˚C for second centrifugation step 
 
1) Place beads in rounded part of a 2 mL safe-lock tube 
2) Add 0.125-0.25 g of sample to tube. Sample tubes can be frozen until needed to 
extraction. 
3) Add 300 uL SLX-Mlus buffer. I use 700 uL for fecal samples to prevent sludge 
problems. 
4) Use tissue lyzer to beat bead tubes for 10 min at frequency 20 
5) Spin down foam by centrifuging at 5000 x g for 2 min at room temp. 
 Gets the foam off the cap. 
6) Add 30 uL DS buffer and 2 uL RNase A 
 a) 30 uL x 110 rxns = 3.3 mL 
 b) 2 uL x 110 rxns = 220 uL 
 c) Mix together in a small conical tube 
 d) Dispence 32 uL to each tube 
7) Vortex to mix thoroughly. 
8) Place tubes in 90˚C water bath for 5-7 min. 
9) Briefly vortex tubes once during incubation. I do this after 3.5 min. 
10) Centrifuge 5000 x g for 10 at room temp. 
11) Transfer 1000 uL supernatant into a new set of 1.5mL tubes. 
 a) You likely won’t have this much. Don’t be afraid to transfer cloudly liquid. 
12) Add 67 uL of SP2 buffer and 67 uL cHTR reagent 
a) Warm up cHTR to 37˚C to make sure there are no solids in the bottle. Put back 
in fridge after use. 
b) Solution will be very thick to add. Sanitize a razor blade and cut the tip off a 
pipette tip for use. 
13) Vortex to mix. 
14) Let sit on ice for 5 min. 
15) Centrifuge at 5000 x g for 10 min at 4˚C. 
16) Transfer the supernatant into a new tube. You may have to take some sludgy stuff. 
17) Can leave at this step for overnight. 
 
Preparation of nucleic acids – do prior to extraction 
 
18) Make 100 mL of 70% EtOH (make fresh everytime) 
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19) Make 10 mM sodium acetate 
 a) g needed = MW (g/mol) x volume needed (L) x final conc (M) 
b) 82.03 g/mole x 0.05 L x 0.01 M = 0.041 g measured into 50 mL ddiH20 
20) Get ice bucket 
21) Put EtOH and isopropanol into ice bucket 
22) Make 10 mM Tris at pH 8 
 a) Tris base = 121 g/mol 
 b) To make 1 L 
  i. 10 mM = 0.01 M 
ii. (0.01 mol/L) * (121 g/mol)  = 1.21 g/L 
iii. Sterilize by autoclave 
iv. Let cool to room temp 
v. pH to 8 (for 250 mL I added approximately 30 uL, but adjust as needed) 
Note: pH solution prior to autoclaving if you are worried about sterility. 
pH shouldn’t change much. 
23) Add 10 mM of sodium acetate to each lysate tube, vortex gently, and incubate on ice 
for 5 min (solution is to 0.2X of beginning volume) 
 a. 350 uL * 0.2 = 70 uL added, I would just add 70 uL regardless of volume 
24) Centrifuge tubes at 16,000 x g for 15 min at 4˚C. 
25) Transfer supernatant into new 1.5 mL tube 
 a. If less than 650 uL transfer all to one tube. There likely won’t be more than 600 
uL 
26) Add one volume (same amount as supernatant from previous step) of isopropanol to 
supernatant tube and vortex 
 a. I added 300-400 uL  
27) Incubate tubes on ice for 30 min 
28) Centrifuge at 4˚C for 15 min at 16,000 x g 
29) Pipette out supernatant and discard (you can just decant) 
30) Wash nucleic acid pellet with 500 uL ice cold 70% EtOH and gently vortex 
 a. Removes residual salt 
31) Centrifuge at room temp for 2 min at 13,000 x g 
32) Decant wash and dry pellet for 3 min 
33) Dissolve the nucleic acid pellet in 450 uL of Tris (10 mM, pH 8) and transfer to a 
deep well plate (DWP). 
 a. Its best to let samples set at 4˚C for a few hours or overnight. (I do this in the 
tubes) 
 b. There may be a slight pellet so just mix gently and transfer to DWP. Mix with 
pipette. 
  c. Verify samples match paper chart 
 d. Samples or DWP can be frozen until King Fisher step is done. 
 
King Fisher Isolation 
34) Add 0.5 volumes of XP2 buffer, 10 uL Mag-Bind Particles CND, and 5 uL Binding 
Enhancer to DWP containing DWP. (I do this prior to putting samples in DWP.) 
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a. The XP2 buffer, Mag-Bind Particles, and Binding Solution can be prepared in a 
Master Mix. 
  i. 225 uL x 110 = 24,750 uL = 24.75 mL XP2 buffer 
  ii. 10 uL x 110 = 1100 uL = 1.1 mL Mag-Bind CND 
  iii. 5 uL x 110 = 550 uL Binding Enhancer 
  iv. Add 240 uL of this solution to each well of lysate plate 
35) Add 300 uL XP2 buffer to a new DWP, 33 mL 
36) Add 300 uL VHB buffer to a new DWP, 33 mL 
37) Add 400 uL SPM Wash buffer to a new DWP, 44 mL 
38) Add 400 uL SPM Wash buffer to a new DWP, 44 mL  
39) Add 130 uL Elution buffer to a new DWP, 14.3 mL 
40) Place plates on Kingfisher in correct areas when prompted by machine using protocol 
Omega_noH2O 
 a. Takes 30 min 
b. Make sure to have an additional sterile DWP and tip comb every time.  
c. DWP for tip comb can be reused, just place silver tape on it 
41) Save samples plate and elution plate and cover with silver tape and freeze. 
42) Transfer 50 uL of elution into a 96 well plate for downstream analysis 
 
 
PCR Primer Step 
43) Thaw elution plate and bacterial primer plate on ice or in fridge. Make sure primer 
plate number matches your plate number (1 for 1, 2 for 2, etc.) 
44) Remove Terra Box from freezer to thaw. 
 PCR recipe 
Recipe 1 rxn 100 rxn 
Terra Buffer 12.5 uL 1250 uL = 1.25 mL 
Terra Polymerase 0.5 uL 50 uL 
Primer 1.0 uL These are individual per well 
H20 9.0 uL 900 uL = 0.9 mL 
DNA 2.0 uL 200 uL 
Total 25.0 uL 2500 uL = 2.5 mL 
45) Spin elution and primer plates in centrifuge at 3000 rpm for 1 min 
46) Add reagents to PCR plate 
a. Master mix = Buffer + polymerase + H20 = 22 uL, can place in  
b. Primer = 1 uL 
c. DNA = 2 uL 
d. Seal with a plate cover, make sure its well sealed 
e. Spin PCR plate down. 
47) Turn on PCR machine and place plate in holder 
48) Use the “Illumina PCR 25c” protocol, 25 uL of total reaction 
Stage 1 2 2 2 3 3 
Step 1 1 2 3 1 2 
Temp, ˚C 98 98 55 68 68 4 
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Time, 
m:ss 
3:00 0:30 0:30 0:45 4:00 ∞ 
Repetition x1 x25 x1 
 
49) When PCR is finished, spin down plate. Plate can be covered with silver tape and 
frozen or proceed to agarose gel. 
 
DNA Agarose Gel Electrophoresis 
50) Make an 1.5% agarose gel with 2 50-well combs 
 a. 250 mL TBE buffer + 3.75 g agarose 
 b. Microwave carefully until agarose has dissolved, make sure to avoid boil over 
c. Temper media, add 12.5 uL of ethidium bromide and mix  
d. Prior to pouring into gel casting frame. Add combs. 
e. Let gel polymerize for an hour 
51) Spin down PCR plate at 3000 rpm for 1 min.  
52) Add 5 uL of PCR product to PCR plate and 3 uL of Xylene loading dye to each well    
53) Seal primer plate with silver tape and freeze for later use. 
54) Spin down loading dye plate. 
55) Remove 50 kb ladder from freezer 
56) Remove gel from casting frame and place in running box with buffer, remove combs 
and make sure buffer floods all wells. 
57) Add ladder to the first well on each well set. 
58) Use multichannel to load samples into wells.  
59) Plug in apparatus to power source and run at 120 V, 75 ?amps, and 60-75 mins. 
60) Remove gel from buffer and place in gel doc to image gel. 
 a. Take a picture and double check bands. Clear bands are good. Smearing is boo 
bad. 
 
Normalization Step 
61) Make sure PCR Amplified plate is thawed and spun down.  
62) Add 20 uL of sample to a 96 well Binding plate (brand name), do not put tips in 
bottom of wells. 
63) Cover and spin down. 
64) Turn on epMotion robot.  
a. 96 well plate and solutions come from Charm Biotech 96 PCR Purification and 
Normalization kit 
b. Place 96 well plate on area B1. (The spot that holds a plate.) 
c. Place new tip boxes on A2 and B2. 
d. Place cartridge containing buffers on C2. 
 i. Solutions will be added to epMotion 30 mL Reservoirs. 
 ii. Binding solution, leftmost spot, and minimum of 2.125 mL needed 
 iii. Washing buffer, next spot, minimum of 9.805 mL needed. 
 iv. Elution buffer, next spot, minimum of 2.125 mL needed. 
v. Reservoir covers should be taken off and placed under the machine for 
coverage.  
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e. Empty used tip bin if not done already. Keep an eye on this to avoid having tips 
get stuck on the robot pipette and causing problems. 
f. Load “Normalizationnewkit50” protocol on computer. 
 i. Add 20 uL of binding solution to all wells. 
 ii. Incubate for 60 min. 
iii. Dump out liquid and spin plate upside down on a paper towel for 1 min 
at 3000 rpm. Place plate back in the robot. 
iv. Add 50 uL of washing buffer, incubate 30 sec, repeat step iii. Put a new 
rack of tips in A2. 
v. Repeat step iv. 
vi. Wait 2 min, add 20 uL of Elution buffer. 
g. Click “Run” tab, check “HEPA” box, well volume should be 20 uL, make sure 
buffers meet minimum quantity. Add more volume for column next to minimum. 
h. Robot might not recognize tip boxes, make sure tips are there and ignore 
warning. Robot will also complain solution cartridge, click “Ignore” 
i. Door can lifted to halt robot at anytime, close to resume. 
65) Cover plate, vortex for 30 sec, spin down. 
 
Pooling Sample libraries 
66) Use epMotion robot again. Select “pooling_10uL_VWRtips” protocol. 
 a. Protocol will take 10 uL from each well and pool it in the 1.5 mL tube. 
67) Place a new box of tips in A2. Dump used tip bin. 
68) Place Blunting cartridge in C2, add clean 1.5 mL tube to the A1 position (top left 
corner) 
69) Click  “Run” tab. Check HEPA box, click through “Next” steps until start. 
70) When finished, cover plate with silver tape and freeze. Label tube and freeze or 
continue to purification step. 
 
Purification of DNA library 
71) Follow protocol for “PCR clean-up “ of NucleoSpin Gel and PCR Clean-up kit. Use 
1:2 dilution. 
a. Adjust DNA binding condition 
For very small sample volumes < 30 uL adjust the volume of the reaction 
mixture to 50-100 uL with water. 
Mix 1 volume of sample with 2 volumes of Buffer NTI  
960 uL of DNA + 1920 uL of Mix, Mix is 1:2, 640 NTI buffer + 1280 
PCR H2O     
b. Bind DNA 
Place a Nucleospin Gel and PCR Clean-up Column into a Collection Tube 
(2 mL) and load up to 700 uL sample.  
Centrifuge for 30 s at 11,000 x g. Discard flow-through and place the 
column back into the collection tube. 
Load remaining sample if necessary and repeat the centrifugation step.  
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c. Add 700 uL Buffer NT3 to the NucleoSpin Gel and PCR Clean-up Column. 
Centrifuge for 30 s at 11,000 x g. Discard flow-through and place the column 
back into the collection tube. 
Repeat previous washing step to minimize chaotropic salt carry-over and 
improve A260/A230 values. 
 d. Dry silica membrane 
Centrifigure for 1 min at 11,000 x g to remove Buffer NT3 completely. 
Make sure the spin column does not come in contact with the flow-
through while removing it from the centrifuge and the collection tube. 
 e. Elute DNA 
Place the Nucleospin Gel nad PCR Clean-up Column into a new 1.5 mL 
microcentrifuge tube. Add 15-30 uL Buffer NE and incubate at room 
temperature (18-25℃) for 1 min. Centrifuge for 1 min at 11,000 x g.  
72) Label tube with plate number and freeze. 
 
Quantification of DNA library 
 
73) Use DeNovix kit and reader. You must use DeNovix tubes for procedure. 
74) Making working solution (WS) 
a. Make sure buffer and dye are at room temp when used. You can take an aliquot 
of the buffer so you don’t have to get the whole bottle to temp. 
b. 200 uL buffer + 2.0 uL dye for each library and standard. Add an extra 0.5 to 
provide room for pipetting error. (2 standards + 4 library + 0.5 extra = 6.5 
libraries) 
c. 200 uL buffer x 6.5 = 1300 uL buffer, 2.0 uL dye x 6.5 = 13.0 uL dye 
75) Add working solution to tubes labeled for standards and samples. 
a. Standards need to be made each day for quantification. 
b. Don’t add standard or sample library until ready to proceed. 
 c. 190 uL WS + 10 uL of 0 standard 
 d. 190 uL WS + 10 uL of 25 standard 
 e. 199 uL WS + 1 uL sample library (Make one for each sample library) 
 
76) Follow procedure for standards and samples, one at a time: 
 a. Launch Fluoro dsDNA app using DeNovix fluorometer. 
b. Use drop down menu to select “DeNovix dsDNA Ultra High Sensitivity 
Assay” 
c. Select “Preconfigured 2 standards” and then choose “Generate New Standard 
Curve” 
  d. Add 0 standard to tube. 
e. Spin briefly on mini centrifuge to ensure samples are mixed together. 
f. Time for 5 min 
g. Place tube in Fluorometer slot and close lid, tap “Measure” to measure. 
h. Add 25 standard to tube and repeat steps e, f, and g. 
i. After both standards have been run, tap the “Samples” button. 
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j. Add sample library DNA to respective tube and repeat steps e, f, and g. Write 
down concentration. 
k. Repeat until all libraries have been run. 
77) Enter concentrations into Excel file “Library Dillution Calculator Illumina”. This will 
convert pg/mL to nM. 
78) Determine dilutions needed to created 4 nM libraries for pooling. (Need to add to this 
once I have hit this step. 
 a. C1V1=C2V2 
 
Aligent High Sensitivity DNA Kit Quick Start Guide For Bioanalyzer Chip 
Preparing the Gel-Dye Mix 
1. Allow high sensitivity DNA dye concentrate (blue) and high sensitivity DNA gel 
matrix (red) to equilibrate to room temperature for 30 min. 
2. Add 15 uL of high sensitivity DNA dye concentrate (blue) to a high sensitivity 
DNA gel matrix vial (red). 
3. Vortex solution well and spin down. Transfer to spin filter.  
4. Centrifuge at 2240 g +/- 20% for 10 min. Protect solution from light. Store at 4℃. 
Use prepared gel-dye mix within 6 weeks of preparation  
Loading the Gel-Dye Mix 
1. Allow the gel-dye mix to equilibrate to room temperature for 30 min before use. 
2. Put a new high sensitivity DNA chip on the chip priming station. 
3. Pipette 9 uL of gel-dye mix in the well marked G with white lettering and a black 
circle around it. 
4. Make sure that the plunger is positioned at 1 mL and then close the chip priming 
station. 
5. Press plunger until it is held by the clip. 
6. Wait for exactly 60 s then release clip. 
7. Wait for 5 s, then slowly pull back the plunger to the 1 mL position. 
8. Open the c hip priming station and pipette 9 uL of gel-dye mix in the wells 
marked G with black lettering, white surrounding. 
Loading the Marker 
1. Pipette 5 uL of marker (green) in all sample and ladder wells. Do not leave any 
wells empty. 
Loading the Ladder and Samples 
1. Pipette 1 uL of high sensitivity DNA ladder (yellow) in the well marked with a 
ladder. 
2. In each of the 11 sample wells pipette 1 uL of sample (used wells) or 1 uL of 
marker (unused wells).  
3. Put the chip horizontally in the adapter and vortex for 1 min at the indicated 
setting (2400 rpm). 
4. Run the chip in the Agilent 2100 Bioanalyzer instrument within 5 min.  
 
 
Sodium Acetate and Ethanol DNA Library Precipitation 
1. Add 1/10 volume sodium acetate (3M, pH=5.2). 
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2. Add 2.5X volume (calculated after addition of sodium acetate) of at least 100% 
isopropanol. 
3. Add 1.0 uL Carrier RNA from Qiagen kit to tube. 
4. Incubate at -80℃ overnight. 
5. Centrifuge at >14,000 x g for 30 min at room temperature to 4℃. 
6. Discard supernatant carefully, making sure the DNA pellet (may not be visible) is 
not discarded.  
7. Rinse with cold 50 uL 70% EtOH. 
8. Centrifuge for 15 min at 4℃. 
9. Discard supernatant and dissolve pellet in TE or EB. Make sure buffer comes in 
contact with the whole surface of the tube since a significant portion of DNA may 
be deposited in the walls instead of in the pellet.  
*** Don’t resuspend pellet until sequencing, trying to minimize library 
concentrate degradation.  
 
BluePippin Purification Protocol – 1.5% Agarose Gel Cassette 
1. Prepare DNA samples 
a. Bring DNA sample up to 30 uL with TE. 
b. Bring loading solution to room temperature. 
c. For each sample, combine 30 uL of DNA sample with 10 uL of leading 
solution/marker mix (labeled K). 
d. Mix samples thoroughly (vortex mixer). Brieflky centrifuge to collect. 
2. Program a Protocol 
a. In the Pippin Prep Software, go to the Protocol Editor Tab. 
b. Click “Cassette” folder, and select “1.5% DF Marker K”. 
c. Select the collection mode for each lane (usually “Tight” or “Range”_, and 
enter the size selection parameters. 
d. Click the “Use Internal Standards” button. 
e. Make sure the “Ref Lane” values match the lane numbers. 
f. Press “Save As” and name and save the protocol.  
3. Calibrate the Optics with the Calibration Fixture 
a. Place the calibration fixture onto the optical nest. Close the lid. 
b. Press “CALIBRATE” to launch the calibration window. 
c. Enter 0.80 in the “Target I ph, mA” field. Press “CALIBRATE” boutton 
in the window, and when complete press “EXIT”. 
4. Inspect the Gel Cassette 
a. Remove the cassette from the foil packaging. 
b. Inspect the levels of buffer in all buffer reservoirs. Reservoirs should be 
nearly full. If the buffer level in any reservoir appears less than 50% full, 
fill with spare buffer. 
c. Inspect the gel columns. Look for obvious breakage of the agarose column 
in each channel. If there is obvious breakage, do not use the lane. 
Remaining lanes can be used. 
d. Inspect for bubbles due to separation of agarose from bottom of cassette in 
the region used for optical detection of DNA. If a bubble is observed, do 
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not use the lane. A bubble on the top of the gel column will not affect 
detection.  
5. Prepare the Cassette for Loading 
a. Dislodge bubbles from behind the elution wells. Tilt the cassette sample 
well side down, to release the any trapped bubbles behind the elution 
modules. 
b. Place Cassette into the optical nest. Keep the cassette slightly tilted down 
so that the bubbles in the elution reservoirs don’t return to the area behind 
the elution modules. Be sure the cassette is fully seated into the bottom of 
the nest to ensure proper optical alignment. 
c. Remove the white tabbed adhesive strips from the cassette. Place one hand 
on the cassette, and hold it firmly in the nest. Grab the white tabs of the 
tape and pull the strips firmly and slowly toward the front of the 
BluePippin until they are removed. 
d. Remove buffer from all elution modules and replace with 40 uL of fresh 
electrophoresis buffer. Make sure that the pipette tips extend all the way to 
the bottom of the elution modules without sealing the elution port opening. 
Test tip fit using the empty rinse cassette supplied with the instrument. 
e. Seal the elution wells with the adhesive tape strips. Tape for sealing the 
elution wells are supplied with cassette packaging. Place tape over the 
elution wells and rub firmly to fix the tape in position. 
f. Check the buffer level in the sample wells. Immediately prior to loading, 
sample wells should be completely filled to the top with buffer. If any 
wells are underfilled, top them with additional buffer. 
g. Perform the continuity test. Close the lid and press the “Test” button 
located in the lower right area of the Main screen. The test routine runs 
automatically and measures the current in each separation and elution 
channel. And should return a “PASS” for each separation and elution 
channel. The cassette temperature must be above 17℃(62℉). 
6. Load Samples 
a. Re-check the buffer level in the sample wells. Make sure that sample wells 
are completely full to the top with electrophoresis buffer. Fill with 
additional buffer, if necessary. 
b. Remove 40 uL of buffer from the first sample well, and load 40 uL of 
sample into that well. Take care to not pierce the agarose with the pipette 
tip. There is gel on all sides and bottom of the sample well. In addition, 
there is an agarose “chimney” surrounding the top of the sample well that 
protrudes up through the cassette cover. When removing buffer, some 
users find it useful to immerse the pipette tip just below the surface of the 
buffer and follow the liquid level down with the tip as the buffer is 
removed. When buffer removal is completed, there will be ~30 uL of 
buffer left in the well. When adding sample, place tip of pipette just below 
the surface of the buffer, and follow the liquid level up with the tip as the 
well fills. Don’t be concerned if the sample well slightly overfills. The 
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density of the sample will allow it to sink before it can flow out of the 
well.  
c. Repeat step b for the remaining four wells. 
7. Run 
a. Close the lid, go to the Main Tab, and make sure the proper protocol is 
loaded in the “Protocol Name” field. 
b. Press “START”. The run will automatically stop when every collection is 
complete. 
8. Collect Fractions 
a. Remove sampels using a standard 100-200 uL pipette. Samples will be in 
a Tris-TAPS buffer at a volume of 40 uL. Samples should be suitable for 
amplification. Do not let samples remain in cassette overnight. 
b. Remove cassette and dispose of properly. Do not keep used cassettes in 
the Pippin with the cover closed. Humidity from the cassette may cause 
damage to electrodes.  
 
NextSeq System Denature and Dilute Libraries Guide 
1. Denature Libraries 
a. Combine 5 uL of DNA library and 5 uL 0.2 N NaOH in a microcentrifuge 
tube. 
b. Vortex briefly and then centrifuge at 280 x g for 1 minute. 
c. Incubate at room temperature for 5 minutes. 
d. Add the following volume of 200 mM Tris-HCl, pH 7.  
e. Vortex briefly and then centrifuge at 280 x g for 1 minute.  
2. Dilute Denatured Libraries to 20 pM. 
a. Add the following volume of prechilled HT1 to the tube of denatured 
libraries.  
i. 985 uL for 4 nM 
ii. The result is a 20 pM denatured library. 
b. Vortex briefly and then centrifuge at 280 x g for 1 minute. 
c. Place the 20 pM libraries on ice until you are ready to proceed to final 
dilution.  
Speed-Vacuum DNA Concentration 
1. Using Denovix kit, determine concentration of DNA present in elution buffer 
and how much elution buffer needed to achieve optimal concentration.  
2. Place microcentrifuge tube containing library in Speed-Vacuum with tube cap 
open and a balance and close the lid.  
3. Turn on centrifuge portion of vacuum followed by the vacuum pump.  
4. Monitor amount of fluid present in library until desired concentration is 
achieved.  
5. Shut off vacuum and centrifuge. 
6. Check concentration with Denovix again.  
 
MiSeq Library Preparation and Sequencing  
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1. Remove a 500 cycle reagent cartridge from the -20 ℃ freezer. Place in room 
temperature water bath for one hour. Place HT1 buffer tube in 4 ℃ fridge. 
2. Copy sample sheet to sample sheet folder on MiSeq. Rename sample sheet to 
match barcode of reagent cartridge.  
3. When the reagent cartridge has thawed, dry bottom with paper towel. Invert 
the cartridge repeatedly to check each well is thawed. This also served to mix 
the reagents. Place in hood. 
4. Thaw library, PhiX, and sequencing primers. Check to make sure HT1 is 
thawed.  
5. Place 3 uL of the Read 1 Sequencing Primer(s) into a clean PCR tube. Repeat 
in separate tubes for the Index Primer(s) and Read 2 Sequencing Primer(s). 
6. Using a 1000 uL pipette tip, break the foil over wells 12, 13, 14, and 17.  
7. Use an extra long 100 uL tip with the pipettor set on 75 uL to transfer the 3 uL 
of Read 1 Sequencing Primer to the bottom of well 12 and pipette 10X to mix. 
Repeat this process spiling the Index primer into well 13 and the Read 2 
Sequencing Primer into well 14.  
8. Prepare a fresh dilution of 0.2N NaOH. 
9. To a 1.5 mL tube add 10 uL of library, and 10 uL of 0.2N NaOH. To a 
separate tube add 2 uL PhiX, 3 uL PCR grade water, and 5 uL of 0.2N NaOH. 
Vortex both tubes to mix and spin for 1 minute at 400rcf.  
10. Allow the tubes to incubate at room temperature for 5 minutes. Immediately 
add 980 uL of HT1 to library tube and 990 uL HT1 to the PhiX tube. 
11. Use HT1 to dilute both the library and PhiX to 10pM. For a 5% PhiX run, 
combine 950 uL of 3.5pM Library and 50 uL PhiX in a final tube. Vortex. 
Load 600 uL of this solution into well 18 on the reagent cartridge. See 
example below: 
a. (1.45 nM library x 10 uL) + (0.2N NaOH x 10 uL) + 980 uL HT1 = 
14.5 pM Lib, 0.002N NaOH 
b. (14.5pM lib x 241.38 uL + 758.62 uL HT1 = 3.5pM lib, 0.00048N 
NaOH 
c. [(10nM PhiX x 2 uL) + 3 uL H2O] + (0.2N NaOH x 5 uL) + 990 uL 
HT2 = 20pM PhiX, 0.001 NaOH 
d. (20pM PhiX x 175 uL) + 825 uL HT1 = 3.5 PhiX, 0.0000175N NaOH  
e. (3.5pM Lib x 950 uL) + (3.5M PhiX x 50 uL) = solution loaded 
f. Solution loaded is 3.5pM overall with a 3.325 pM library 
concentration, 0.175 PhiX concentration, and 0.0000457N NaOH 
12. Set reagent cartridge aside. Unbox flow cell and PR2 bottle. 
13. Thoroughly rinse the flow cell with Milli-Q water. Carefully dry by blotting 
with lint free wipes. Give special attention to the edges and points of 
intersection between the glass and plastic. 
14. We a new wipe with 100% alcohol and wipe the glass on both sides avoiding 
the rubber intake ports. 
15. Visually inspect the flow cell to ensure there are no blemishes, particles, or 
fibers on the glass. 
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16. Follow the screen instructions and load the flow cell, reagent cartridge, and 
PR2 bottle. Empty and replace the waste bottle. 
17. Ensure the machine recognizes the correct sample sheet and the run 
parameters are correct. 
18. Wait for the MiSeq to perform its pre-run check, and press start.  
 
